Cancer Research and Treatment

Original Articles

General

Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients: Wonyoung Choi, Yun-Hee Kim, Sang Myung Woo, Yebeen Yu, Mi Rim Lee, Woo Jin Lee, Jung Won Chun, Sung Hoon Sim, Heejung Chae, Hyoeun Shim, Keun Seok Lee, Sun-Young Kong; Cancer Res Treat. 2023;55(4):1077-1086. Published online June 12, 2023; DOI: https://doi.org/10.4143/crt.2022.1630

Abstract PDF Supplementary Material PubReader ePub

Purpose
Patient-derived tumor cells can be a powerful resource for studying pathophysiological mechanisms and developing robust strategies for precision medicine. However, establishing organoids from patient-derived cells is challenging because of limited access to tissue specimens. Therefore, we aimed to establish organoids from malignant ascites and pleural effusions.
Materials and Methods
Ascitic or pleural fluid from pancreatic, gastric, and breast cancer patients was collected and concentrated to culture tumor cells ex vivo. Organoids were considered to be successfully cultured when maintained for five or more passages. Immunohistochemical staining was performed to compare the molecular features, and drug sensitivity was assayed to analyze the clinical responses of original patients.
Results
We collected 70 fluid samples from 58 patients (pancreatic cancer, n=39; gastric cancer, n=21; and breast cancer, n=10). The overall success rate was 40%; however, it differed with types of malignancy, with pancreatic, gastric, and breast cancers showing 48.7%, 33.3%, and 20%, respectively. Cytopathological results significantly differed between successful and failed cases (p=0.014). Immunohistochemical staining of breast cancer organoids showed molecular features identical to those of tumor tissues. In drug sensitivity assays, pancreatic cancer organoids recapitulated the clinical responses of the original patients.
Conclusion
Tumor organoids established from malignant ascites or pleural effusion of pancreatic, gastric, and breast cancers reflect the molecular characteristics and drug sensitivity profiles. Our organoid platform could be used as a testbed for patients with pleural and peritoneal metastases to guide precision oncology and drug discovery.

Citations

Citations to this article as recorded by

The use of patient-derived xenografts and patient-derived organoids in the search for new therapeutic regimens for pancreatic carcinoma. A review
Emin Gayibov, Tomáš Sychra, Alžběta Spálenková, Pavel Souček, Martin Oliverius
Biomedicine & Pharmacotherapy.2025; 182: 117750. CrossRef
Precision Medicine for Peritoneal Carcinomatosis—Current Advances in Organoid Drug Testing and Clinical Applicability
Harleen Kaur, Josephine A. Wright, Daniel L. Worthley, Elizabeth Murphy, Susan L. Woods
Organoids.2025; 4(1): 2. CrossRef
Three-dimensional models: from cell culture to Patient-Derived Organoid and its application to future liposarcoma research
SAYUMI TAHARA, SYDNEY RENTSCH, FERNANDA COSTAS CASAL DE FARIA, PATRICIA SARCHET, ROMA KARNA, RAPHAEL E. POLLOCK, FEDERICA CALORE
Oncology Research.2025; 33(1): 1. CrossRef
PRMT1 promotes pancreatic cancer development and resistance to chemotherapy
Bomin Ku, David Eisenbarth, Seonguk Baek, Tae-Keun Jeong, Ju-Gyeong Kang, Daehee Hwang, Myung-Giun Noh, Chan Choi, Sungwoo Choi, Taejun Seol, Hail Kim, Yun-Hee Kim, Sang Myung Woo, Sun-Young Kong, Dae-Sik Lim
Cell Reports Medicine.2024; 5(3): 101461. CrossRef
Establishment and Advancement of Pancreatic Organoids
Dong Hyeon Lee
Keimyung Medical Journal.2024; 43(1): 3. CrossRef
Organoid as a promising tool for primary liver cancer research: a comprehensive review
Xuekai Hu, Jiayun Wei, Pinyan Liu, Qiuxia Zheng, Yue Zhang, Qichen Zhang, Jia Yao, Jingman Ni
Cell & Bioscience.2024;[Epub] CrossRef
The use of organoids in creating immune microenvironments and treating gynecological tumors
Ling-Feng Zhou, Hui-Yan Liao, Yang Han, Yang Zhao
Journal of Translational Medicine.2024;[Epub] CrossRef
The pros and cons of mechanical dissociation and enzymatic digestion in patient-derived organoid cultures for solid tumor
Jing Ren, Mengli Liu, Mingjie Rong, Xuan Zhang, Gang Wang, Yihan Liu, Haijun Li, Shichao Duan
Cell Organoid.2024;[Epub] CrossRef
Organoid: Bridging the gap between basic research and clinical practice
Guihu Weng, Jinxin Tao, Yueze Liu, Jiangdong Qiu, Dan Su, Ruobing Wang, Wenhao Luo, Taiping Zhang
Cancer Letters.2023; 572: 216353. CrossRef

5,677 View
503 Download
5 Web of Science
9 Crossref

A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy: Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim; Cancer Res Treat. 2023;55(4):1096-1103. Published online April 7, 2023; DOI: https://doi.org/10.4143/crt.2022.1565

Abstract PDF Supplementary Material PubReader ePub

Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by

Evaluation of self-assembling properties of paclitaxel-biotin conjugates
Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
Nano-Structures & Nano-Objects.2024; 40: 101375. CrossRef

3,687 View
219 Download
1 Crossref

Breast cancer

Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies: Yong Wha Moon, Seung Ki Kim, Keun Seok Lee, Moon Hee Lee, Yeon Hee Park, Kyong Hwa Park, Gun Min Kim, Seungtaek Lim, Seung Ah Lee, Jae Duk Choi, Eunhye Baek, Hyesun Han, Seungjae Baek, Seock-Ah Im; Cancer Res Treat. 2023;55(3):766-777. Published online January 19, 2023; DOI: https://doi.org/10.4143/crt.2022.987

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the consistent efficacy and safety of eflapegrastim, a novel long-acting granulocyte-colony stimulating factor (G-CSF), in Koreans and Asians compared with the pooled population of two global phase 3 trials.
Materials and Methods
Two phase 3 trials (ADVANCE and RECOVER) evaluated the efficacy and safety of fixed-dose eflapegrastim (13.2 mg/0.6 mL [3.6 mg G-CSF equivalent]) compared to pegfilgrastim (6 mg based on G-CSF) in breast cancer patients who received neoadjuvant or adjuvant docetaxel/cyclophosphamide. The primary objective was to demonstrate non-inferiority of eflapegrastim compared to pegfilgrastim in mean duration of severe neutropenia (DSN) in cycle 1, in Korean and Asian subpopulations.
Results
Among a total of 643 patients randomized to eflapegrastim (n=314) or pegfilgrastim (n=329), 54 Asians (29 to eflapegrastim and 25 to pegfilgrastim) including 28 Koreans (14 to both eflapegrastim and pegfilgrastim) were enrolled. The primary endpoint, DSN in cycle 1 in the eflapegrastim arm was non-inferior to the pegfilgrastim arm in Koreans and Asians. The DSN difference between the eflapegrastim and pegfilgrastim arms was consistent across populations: –0.120 days (95% confidence interval [CI], –0.227 to –0.016), –0.288 (95% CI, –0.714 to 0.143), and –0.267 (95% CI, –0.697 to 0.110) for pooled population, Koreans and Asians, respectively. There were few treatment-related adverse events that caused discontinuation of eflapegrastim (1.9%) or pegfilgrastim (1.5%) in total and no notable trends or differences across patient populations.
Conclusion
This study may suggest that eflapegrastim showed non-inferior efficacy and similar safety compared to pegfilgrastim in Koreans and Asians, consistently with those of pooled population.

Citations

Citations to this article as recorded by

Comparison of Prophylactic Efficacy of Eflapegrastim and Pegteograstim for Chemotherapy-induced Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX/mFOLFIRINOX
Eui Seon Lee, Min Jung Geum, Jong Hee Ko, Jae Song Kim, Eun Sun Son, Yun Mi Yu
Journal of Korean Society of Health-System Pharmacists.2024; 41(3): 253. CrossRef

4,855 View
274 Download
1 Crossref

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03): Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, Jin-Hee Ahn, Joohyuk Sohn, Jin Seok Ahn, Moon Hee Lee, Jee Hyun Kim, Kyung Eun Lee, Hyo Jung Kim, Si-Young Kim, Yeon Hee Park, Chan-Young Ock, Kyung-Hun Lee, Sae-Won Han, Sung-Bae Kim, Young Hyuck Im, Hyun Cheol Chung, Do-Youn Oh, Seock-Ah Im; Cancer Res Treat. 2023;55(2):523-530. Published online November 8, 2022; DOI: https://doi.org/10.4143/crt.2022.1360

Abstract PDF PubReader ePub

Purpose
This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.
Materials and Methods
Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.
Results
A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).
Conclusion
This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.

Citations

Citations to this article as recorded by

Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach
Zhengguang Zhang, Tianming Lu, Zhe Zhang, Zixian Liu, Ruoning Qian, Ruogu Qi, Fuqiong Zhou, Min Li
Biochemical Pharmacology.2024; 222: 116117. CrossRef
Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
Pingping Bi, Xi Wang, Rui Liu, Xiuqin Li, Shanrong Wei, Jiawen Zhao, Xin Tan, Fan Zhang, Qing Mao, Ying Zhang, Baoyan Tang, Xueqiong Xun, Rong Guo, Kai Zheng, Shaoqiang Zhou, Shicong Tang
Surgery Open Science.2023; 16: 171. CrossRef

4,893 View
170 Download
2 Web of Science
2 Crossref

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy: Eun-Gyeong Lee, Dong-Eun Lee, Hyun hee Kim, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Heejung Chae, Sung Hoon Sim, Keun Seok Lee, Youngmee Kwon, So-Youn Jung; Cancer Res Treat. 2023;55(2):542-550. Published online September 8, 2022; DOI: https://doi.org/10.4143/crt.2022.834

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods
We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results
Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion
AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker.

Citations

Citations to this article as recorded by

The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response
Di Ai, Eliel N Arrey, Lauren M Postlewait, Yuan Gao, Xiaoxian Li
Histopathology.2025;[Epub] CrossRef
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Athina Stravodimou, Ioannis A. Voutsadakis
Expert Review of Anticancer Therapy.2024; 24(3-4): 117. CrossRef
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
Miseon Lee, Tae-Kyung Yoo, Byung Joo Chae, Ahwon Lee, Yoon Jin Cha, Jieun Lee, Sung Gwe Ahn, Jun Kang
Scientific Reports.2024;[Epub] CrossRef
Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma
Adil Aziz Khan, Sana Ahuja, Kiruthikasri G., Sufian Zaheer
Indian Journal of Surgical Oncology.2024; 15(4): 802. CrossRef
Biomarkers and translational research approaches in breast cancer—an update
Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch
memo - Magazine of European Medical Oncology.2023; 16(1): 42. CrossRef
Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang
Discover Oncology.2023;[Epub] CrossRef

5,342 View
177 Download
6 Web of Science
6 Crossref

Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09): Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, Soojung Hong, Sun Kyung Baek, Soon Il Lee, Moon Young Choi, In Sook Woo; Cancer Res Treat. 2023;55(1):123-135. Published online March 24, 2022; DOI: https://doi.org/10.4143/crt.2021.1561

Abstract PDF Supplementary Material PubReader ePub

Purpose
The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea.
Materials and Methods
We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016.
Results
The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003).
Conclusion
Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients.

Citations

Citations to this article as recorded by

HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients
Boqiang Lyu, Shidi Zhao, Hui Wang, Shouping Gong, Biyuan Wang
Scientific Reports.2025;[Epub] CrossRef
Male breast cancer - a single center experience
Igor Djurisic, Milan Zegarac, Milan Kocic, Vladimir Jokic, Nikola Vucic, Ognjen Petrovic, Nada Santrac, Jovana Koncar, Andjela Ivezic, Srdjan Nikolic
Srpski arhiv za celokupno lekarstvo.2025; 153(1-2): 53. CrossRef
Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer
Meiling Huang, Jingjing Xiao, Changjiao Yan, Rui Ling, Ting Wang
American Journal of Men's Health.2024;[Epub] CrossRef

5,995 View
181 Download
3 Web of Science
3 Crossref

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01): In Hae Park, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Yeon Hee Park, Keun Seok Lee, Sung Hoon Sim, Kyong-Hwa Park, Jee Hyun Kim, Byung Ho Nam, Hee-Jun Kim, Tae-Yong Kim, Kyung-Hun Lee, Sung-Bae Kim, Jin-Hee Ahn, Suee Lee, Jungsil Ro; Cancer Res Treat. 2019;51(1):43-52. Published online February 14, 2018; DOI: https://doi.org/10.4143/crt.2017.562

Abstract PDF PubReader ePub

Purpose
We investigated whether irinotecan plus capecitabine improved progression-free survival (PFS) compared with capecitabine alone in patients with human epidermal growth factor 2 (HER2) negative and anthracycline and taxane pretreated metastatic breast cancer (MBC).
Materials and Methods
A total of 221 patients were randomly assigned to irinotecan (80 mg/m2, days 1 and 8) and capecitabine (1,000 mg/m2 twice a day, days 1-14) or capecitabine alone (1,250 mg/m2 twice a day, days 1-14) every 3 weeks. The primary endpoint was PFS.
Results
There was no significant difference in PFS between the combination and monotherapy arm (median, 6.4 months vs. 4.7 months; hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.63 to 1.11; p=0.84). In patients with triple-negative breast cancer (TNBC, n=90), the combination significantly improved PFS (median, 4.7 months vs. 2.5 months; HR, 0.58; 95% CI, 0.37 to 0.91; p=0.02). Objective response rate was numerically higher in the combination arm, though it failed to reach statistical significance (44.4% vs. 33.3%, p=0.30). Overall survival did not differ between arms (median, 20.4 months vs. 24.0 months; p=0.63). While grade 3 or 4 neutropenia was more common in the combination arm (39.6% vs 9.0%), hand-foot syndrome was more often observed in capecitabine arm. Quality of life measurements in global health status was similar. However, patients in the combination arm showed significantly worse symptom scales especially in nausea/vomiting and diarrhea.
Conclusion
Irinotecan plus capecitabine did not prove clinically superior to single-agent capecitabine in anthracycline- and taxane-pretreated HER2 negative MBC patients. Toxicity profiles of the two groups differed but were manageable. The role of added irinotecan in patients with TNBC remains to be elucidated.

Citations

Citations to this article as recorded by

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef
Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence
José Ángel García-Saenz, Álvaro Rodríguez-Lescure, Josefina Cruz, Joan Albanell, Emilio Alba, Antonio Llombart
Targeted Oncology.2025;[Epub] CrossRef
Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer
Cui-Cui Liu, Lie Chen, Yu-Wen Cai, Yu-Fei Chen, Yi-Ming Liu, Yu-Jie Zhou, Zhi-Ming Shao, Ke-Da Yu
Cell Reports Medicine.2024; 5(2): 101396. CrossRef
Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients
Weili Xiong, Ting Xu, Xiao Liu, Lili Zhang, Yuan Yuan
Cancer.2024; 130(S8): 1488. CrossRef
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Mengqian Ni, Lijia Zhou, Yongkui Lu, Dachuan Guo, Xiuyue Li, Lixia Li, Lidong Zhang, Meiting Chen, Lulu Zhang, Fei Xu, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Anli Yang, Xin An
BMC Cancer.2024;[Epub] CrossRef
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney
npj Breast Cancer.2024;[Epub] CrossRef
A Dual Bispecific Hydrolysis Peptide‐Drug Conjugate Responsive to Micro‐Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple‐Negative Breast Cancer
Tingting Tang, Naiyu Liu, Lingjuan Wang, Kaiyue Zuo, Xinjie Zhu
ChemBioChem.2024;[Epub] CrossRef
Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy
Antonello Pinto, Chiara Guarini, Marianna Giampaglia, Valeria Sanna, Assunta Melaccio, Laura Lanotte, Anna Natalizia Santoro, Francesca Pini, Antonio Cusmai, Francesco Giuliani, Gennaro Gadaleta-Caldarola, Palma Fedele
Pharmaceutics.2024; 16(9): 1146. CrossRef
Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
Yoichi Naito, Seigo Nakamura, Nobuko Kawaguchi-Sakita, Takanori Ishida, Takahiro Nakayama, Yutaka Yamamoto, Norikazu Masuda, Koji Matsumoto, Takahiro Kogawa, Kazuki Sudo, Akihiko Shimomura, Catherine Lai, Danjie Zhang, Yuki Iwahori, Dianna Gary, Danh Huyn
International Journal of Clinical Oncology.2024; 29(11): 1684. CrossRef
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments
Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
International Journal of Cancer.2023; 152(10): 2134. CrossRef
Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review
Salvatore Greco, Nicolò Fabbri, Riccardo Spaggiari, Alfredo De Giorgi, Fabio Fabbian, Antonio Giovine
Biomedicines.2023; 11(6): 1772. CrossRef
Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
Jiao Xie, SiNi Li, YaMin Li, JianHe Li
BMC Health Services Research.2023;[Epub] CrossRef
Triple negative breast cancer: second and successive lines of treatment
Fernando Henao Carrasco, Sara Leal Sánchez
Revisiones en Cáncer.2023;[Epub] CrossRef
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Rebecca A Dent, David W Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A Traina, Petra Vukovic, Darlington Mapiye, Micah J Maxwell, Peter Schmid, Javier Cortés
Future Oncology.2023; 19(35): 2349. CrossRef
An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
Shao-Xian Cheng, Qiu-Chi Chen, Guo-He Lin, Yan-Hong Han, Bi-Cheng Wang, Yi Dai, Yan-Xia Zhao
Medicine.2023; 102(30): e34486. CrossRef
Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
Wensheng Liu, Qiong Du, Zihan Guo, Xuan Ye, Jiyong Liu
Frontiers in Pharmacology.2023;[Epub] CrossRef
Effects of Sacituzumab on Breast Cancer: Target Therapy
Elina Armani Khatibi, Tooba Gholikhani, Balam Jimenez Brito, Nastaran Farshbaf Moghimi
Biomedical Research Bulletin.2023; 1(4): 141. CrossRef
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC
Chris Twelves, Rupert Bartsch, Noa Efrat Ben-Baruch, Simona Borstnar, Luc Dirix, Petra Tesarova, Constanta Timcheva, Lyudmila Zhukova, Xavier Pivot
Clinical Breast Cancer.2022; 22(3): 223. CrossRef
Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future
Fatima Cardoso, David Cella, Galina Velikova, Victoria Harmer, Eva Schumacher-Wulf, Julie Rihani, Ana Casas, Nadia Harbeck
Cancer Treatment Reviews.2022; 102: 102321. CrossRef
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Yi Xiao, Ding Ma, Yun-Song Yang, Fan Yang, Jia-Han Ding, Yue Gong, Lin Jiang, Li-Ping Ge, Song-Yang Wu, Qiang Yu, Qing Zhang, François Bertucci, Qiuzhuang Sun, Xin Hu, Da-Qiang Li, Zhi-Ming Shao, Yi-Zhou Jiang
Cell Research.2022; 32(5): 477. CrossRef
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
F. Miglietta, M. Bottosso, G. Griguolo, M.V. Dieci, V. Guarneri
ESMO Open.2022; 7(2): 100409. CrossRef
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
JAMA Oncology.2022; 8(6): 879. CrossRef
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Kevin Punie, Sagar Sardesai, Erika Hamilton, Delphine Loirat, Tiffany Traina, Roberto Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stephanie Henry, Ingrid Mayer, Yanni Zhu, S
Breast Cancer Research and Treatment.2022; 195(2): 127. CrossRef
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Picc
npj Breast Cancer.2022;[Epub] CrossRef
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo,
npj Breast Cancer.2022;[Epub] CrossRef
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
Dou-Dou Li, Zhong-hua Tao, Bi-Yun Wang, Lei-Ping Wang, Jun Cao, Xi-Chun Hu, Jian Zhang
npj Breast Cancer.2022;[Epub] CrossRef
Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
Jiawei Shou, Fan Mo, Shanshan Zhang, Lantian Lu, Ning Han, Liang Liu, Min Qiu, Hongseng Li, Weidong Han, Dongying Ma, Xiaojie Guo, Qianpeng Guo, Qinxue Huang, Xiaomeng Zhang, Shengli Ye, Hongming Pan, Shuqing Chen, Yong Fang
Frontiers in Immunology.2022;[Epub] CrossRef
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
Min Yan, Peng Yuan, Quchang Ouyang, Ying Cheng, Guohui Han, Dewei Wang, Li Ran, Tao Sun, Da Zhao, Yuju Bai, Shun’e Yang, Xiaojia Wang, Rong Wu, Xiaohua Zeng, Herui Yao, Xuening Ji, Jun Jiang, Xiaohua Hu, Haifeng Lin, Liping Zheng, Zhitu Zhu, Wei Ge, Junla
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
Jasgit C. Sachdev, Pamela Munster, Donald W. Northfelt, Hyo Sook Han, Cynthia Ma, Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, Arunthathi Thiagalingam, Carey Anders
Breast Cancer Research and Treatment.2021; 185(3): 759. CrossRef
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar D. Sardesai, Kevin Kalinsky, Amelia B. Zelnak, Robert Weaver, Tiffany Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab,
New England Journal of Medicine.2021; 384(16): 1529. CrossRef
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset H
npj Breast Cancer.2021;[Epub] CrossRef
Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report
Angelats L, Estival A, Martinez-Cardús A, Musulen E, Margelí M
Current Problems in Cancer: Case Reports.2021; : 100097. CrossRef
A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Jiaojiao Suo, Xiaorong Zhong, Ping He, Hong Zheng, Tinglun Tian, Xi Yan, Ting Luo
Frontiers in Oncology.2021;[Epub] CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef
High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer
Inken Flörkemeier, Tamara N. Steinhauer, Nina Hedemann, Jörg Paul Weimer, Christoph Rogmans, Marion T. van Mackelenbergh, Nicolai Maass, Bernd Clement, Dirk O. Bauerschlag
Cancers.2021; 14(1): 2. CrossRef
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
Jennifer A. Weiss, Andrew Nicklawsky, Jodi A. Kagihara, Dexiang Gao, Christine Fisher, Anthony Elias, Virginia F. Borges, Peter Kabos, Sarah L. Davis, Stephen Leong, Sue Gail Eckhardt, Jennifer R. Diamond
Cancer Medicine.2020; 9(23): 8801. CrossRef
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
Vito Lorusso, Agnese Latorre, Francesco Giotta, Ozkan Kanat
Journal of Oncology.2020; 2020: 1. CrossRef
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca L. Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita C. Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan
New England Journal of Medicine.2019; 380(8): 741. CrossRef
An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine
I. Kümler, R. L. Eefsen, Peter Grundtvig Sørensen, S. Theile, A. Fullerton, P. G. Nielsen, Benny Vittrup Jensen, D. L. Nielsen
Cancer Chemotherapy and Pharmacology.2019; 84(2): 441. CrossRef
Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy
Burak Yasin Aktas, Gurkan Guner, Deniz Can Guven, Cagatay Arslan, Omer Dizdar
Expert Review of Anticancer Therapy.2019; 19(7): 589. CrossRef
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
Jennifer Weiss, Ashley Glode, Wells A. Messersmith, Jennifer Diamond
Expert Review of Anticancer Therapy.2019; 19(8): 673. CrossRef
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
I V Kolyadina, I V Poddubnaya
Journal of Modern Oncology.2018; 20(3): 26. CrossRef

10,805 View
453 Download
38 Web of Science
42 Crossref

Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study: Haeyoung Kim, Won Park, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Yeon-Joo Kim, Eun Sook Lee, Keun Seok Lee, Han-Sung Kang, In Hae Park, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2017;49(4):970-980. Published online January 4, 2017; DOI: https://doi.org/10.4143/crt.2016.382

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy.
Materials and Methods
We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups.
Results
A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI.
Conclusion
We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.

Citations

Citations to this article as recorded by

Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01)
Nalee Kim, Won Park, Haeyoung Kim, Won Kyung Cho, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Kyung Hwan Shin, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Yong Bae Kim
International Journal of Radiation Oncology*Biology*Physics.2025; 121(2): 341. CrossRef
The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies
Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
Frontiers in Oncology.2023;[Epub] CrossRef
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
BMC Cancer.2022;[Epub] CrossRef
What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?
Sang-Won Kim, Won Kyung Cho, Doo Ho Choi, Haeyoung Kim, Oyeon Cho, Won Park, Mison Chun
International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 992. CrossRef
Regional nodal irradiation in pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation
Shin-Hyung Park, Jae-Chul Kim
Radiation Oncology Journal.2020; 38(1): 44. CrossRef
Prediction of nodal staging in breast cancer patients with 1-2 sentinel nodes in the Z0011 era
Fabio Corsi, Luca Sorrentino, Sara Albasini, Daniela Bossi, Carlo Morasso, Laura Villani, Marta Truffi
Medicine.2020; 99(35): e21721. CrossRef
Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy
Xuran Zhao, Yu Tang, Shulian Wang, Yong Yang, Hui Fang, Jianyang Wang, Hao Jing, Jianghu Zhang, Guangyi Sun, Siye Chen, Jing Jin, Yongwen Song, Yueping Liu, Bo Chen, Shunan Qi, Ning Li, Yuan Tang, Ningning Lu, Hua Ren, Yexiong Li
Radiation Oncology.2020;[Epub] CrossRef
Comparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701)
Haeyoung Kim, Heejung Kim, Won Park, Jong Yun Baek, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Jin Ho Kim, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Jee Suk Chang,
Cancers.2020; 12(11): 3261. CrossRef
Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study
Jaeho Kim, Won Park, Jin Kim, Doo Choi, Yeon-Joo Kim, Eun Lee, Kyung Shin, Jin Kim, Kyubo Kim, Yong Kim, Sung-Ja Ahn, Jong Lee, Mison Chun, Hyung-Sik Lee, Jung Kim, Jihye Cha
Cancers.2019; 11(5): 680. CrossRef
Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
Cancer Research and Treatment.2018; 50(4): 1316. CrossRef

10,672 View
319 Download
10 Web of Science
10 Crossref

Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418): Yeon-Joo Kim, Won Park, Boram Ha, Boram Park, Jungnam Joo, Tae Hyun Kim, In Hae Park, Keun Seok Lee, Eun Sook Lee, Kyung Hwan Shin, Haeyoung Kim, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2017;49(4):927-936. Published online December 26, 2016; DOI: https://doi.org/10.4143/crt.2016.508

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy.
Materials and Methods
We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010.
Results
We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081).
Conclusion
PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.

Citations

Citations to this article as recorded by

Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
Munaser Alamoodi
European Journal of Breast Health.2024; 20(2): 81. CrossRef
Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer
Lin-Yu Xia, Wei-Yun Xu, Yan Zhao, Sudeep Gupta
PLOS ONE.2022; 17(6): e0270528. CrossRef
Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
Nalee Kim, Won Park, Won Kyung Cho, Hae Young Kim, Doo Ho Choi, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon
The Breast.2022; 66: 54. CrossRef
Post-mastectomy radiation therapy in breast cancer patients with 1–3 positive lymph nodes: No one size fits all
Majd Kayali, Joseph Abi Jaoude, Arafat Tfayli, Nagi El Saghir, Philip Poortmans, Youssef H. Zeidan
Critical Reviews in Oncology/Hematology.2020; 147: 102880. CrossRef
The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype
Jinli Wei, Yizhou Jiang, Zhimin Shao
The Breast.2020; 51: 40. CrossRef
The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
Lei Zhang, Ru Tang, Jia-Peng Deng, Wen-Wen Zhang, Huan-Xin Lin, San-Gang Wu, Zhen-Yu He
BMC Cancer.2020;[Epub] CrossRef
Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418)
Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha
Cancer Research and Treatment.2019; 51(3): 1041. CrossRef
Effect of postmastectomy radiotherapy on triple-negative breast cancer with T1-2 and 1-3 positive axillary lymph nodes: a population-based study using the SEER 18 database
Jie Zhang, Xiao-Xiao Wang, Jun-Yu Lian, Chuan-Gui Song
Oncotarget.2019; 10(50): 5245. CrossRef
Local and regional recurrence following mastectomy in breast cancer patients with 1–3 positive nodes: implications for postmastectomy radiotherapy volume
Shin-Hyung Park, Jeeyeon Lee, Jeong Eun Lee, Min Kyu Kang, Mi Young Kim, Ho Yong Park, Jin Hyang Jung, Yee Soo Chae, Soo Jung Lee, Jae-Chul Kim
Radiation Oncology Journal.2018; 36(4): 285. CrossRef

11,324 View
346 Download
9 Web of Science
9 Crossref

Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis after Resection of Brain Metastases in Breast Cancer Patients: Boram Ha, Seung Yeun Chung, Yeon-Joo Kim, Ho-Shin Gwak, Jong Hee Chang, Sang Hyun Lee, In Hae Park, Keun Seok Lee, Seeyoun Lee, Tae Hyun Kim, Dae Yong Kim, Seok-Gu Kang, Chang-Ok Suh; Cancer Res Treat. 2017;49(3):748-758. Published online October 31, 2016; DOI: https://doi.org/10.4143/crt.2016.303

Abstract PDF Supplementary Material PubReader ePub

Purpose
In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer.
Materials and Methods
Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015. Among these, 34 received postoperative WBRT (n=24) or PRT (n=10) and 17 did not.
Results
With a median follow-up of 12.4 months (range, 2.3 to 83.6 months), 22/51 patients developed LMCDM at a median of 8.6 months (range, 4.8 to 51.2 months) after surgery. The 18-months LMCDM-free survival (LMCDM-FS) rates were 77.5%, 30.0%, and 13.6%, in the WBRT, PRT, and no RT groups, respectively (p=0.013). The presence of a tumor adjacent to cerebrospinal fluid flow and no systemic treatment after treatment for brain metastases were also associated with poor LMCDM-FS rate. Multivariate analysis showed that WBRT compared to PRT (p=0.009) and systemic treatment (p < 0.001) were independently associated with reduced incidence of LMCDM.
Conclusion
WBRT improved LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients.

Citations

Citations to this article as recorded by

Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer
Joshua Mangerel, Andres Rodriguez-Sein, Daniel Masri
Radiology Case Reports.2025; 20(3): 1620. CrossRef
Revisiting the Role of Surgical Resection for Brain Metastasis
Joonho Byun, Jong Hyun Kim
Brain Tumor Research and Treatment.2023; 11(1): 1. CrossRef
Literature Review: Role of Neurosurgery in Leptomeningeal Carcinomatosis
Thaís Mitie Ogasawara, Thaís Yumi Kobayashi Batista, Rafael Rodrigues Pinheiro dos Santos, Ana Carla Mondek Rampazzo, Caroline Amane Pessoa Badaoui, Igor Ruan de Araújo Caetano, Jonathan Vinícius Martins, Maria Letícia Nogueira, José Ângelo Guarnieri, Car
Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery.2023; 42(04): e337. CrossRef
Iatrogenic Leptomeningeal Carcinomatosis Following Craniotomy for Resection of Metastatic Serous Ovarian Carcinoma: A Systematic Literature Review and Case Report
Brittany M. Stopa, Joshua A. Cuoco, Srijan Adhikari, Douglas J. Grider, Cara M. Rogers, Eric A. Marvin
Frontiers in Surgery.2022;[Epub] CrossRef
Autocrine GMCSF Signaling Contributes to Growth of HER2+ Breast Leptomeningeal Carcinomatosis
Khairul I. Ansari, Arunoday Bhan, Mika Saotome, Antariksh Tyagi, Bony De Kumar, Clara Chen, Motoki Takaku, Rahul Jandial
Cancer Research.2021; 81(18): 4723. CrossRef
Leptomeningeal carcinomatosis in patients with breast cancer
Maria Alice Franzoi, Gabriel N. Hortobagyi
Critical Reviews in Oncology/Hematology.2019; 135: 85. CrossRef
Leptomeningeal Metastases
Jerome J. Graber, Santosh Kesari
Current Treatment Options in Oncology.2018;[Epub] CrossRef
Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study
Seung Yeun Chung, Jong Hee Chang, Hye Ryun Kim, Byoung Chul Cho, Chang Geol Lee, Chang-Ok Suh
Radiation Oncology Journal.2017; 35(2): 153. CrossRef

13,584 View
287 Download
7 Web of Science
8 Crossref

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer: In Hae Park, Joo Hyuk Sohn, Sung Bae Kim, Keun Seok Lee, Joo Seop Chung, Soo Hyeon Lee, Tae You Kim, Kyung Hae Jung, Eun Kyung Cho, Yang Soo Kim, Hong Suk Song, Jae Hong Seo, Hun Mo Ryoo, Sun Ah Lee, So Young Yoon, Chul Soo Kim, Yong Tai Kim, Si Young Kim, Mi Ryung Jin, Jungsil Ro; Cancer Res Treat. 2017;49(3):569-577. Published online September 12, 2016; DOI: https://doi.org/10.4143/crt.2016.289

Abstract PDF PubReader ePub

Purpose
Genexol-PM is a Cremophor EL–free formulation of low-molecular-weight, non-toxic, and biodegradable polymeric micelle-bound paclitaxel. We conducted a phase III study comparing the clinical efficacy and toxicity of Genexol-PM with conventional paclitaxel (Genexol).
Materials and Methods
Patients were randomly assigned (1:1) to receive Genexol-PM 260 mg/m² or Genexol 175 mg/m² intravenously every 3 weeks. The primary outcome was the objective response rate (ORR).
Results
The study enrolled 212 patients, of whom 105 were allocated to receive Genexol-PM. The mean received dose intensity of Genexol-PM was 246.8±21.3 mg/m² (95.0%), and that of Genexol was 168.3±10.6 mg/m² (96.2%). After a median follow-up of 24.5 months (range, 0.0 to 48.7 months), the ORR of Genexol-PM was 39.1% (95% confidence interval [CI], 31.2 to 46.9) and the ORR of Genexol was 24.3% (95% CI, 17.5 to 31.1) (p_{non-inferiority}=0.021, p_superiority=0.016). The two groups did not differ significantly in overall survival (28.8 months for Genexol-PM vs. 23.8 months for Genexol; p=0.52) or progression-free survival (8.0 months for Genexol-PM vs. 6.7 months for Genexol; p=0.26). In both groups, the most common toxicities were neutropenia, with 68.6% occurrence in the Genexol-PM group versus 40.2% in the Genexol group (p < 0.01). The incidences of peripheral neuropathy of greater than grade 2 did not differ significantly between study treatments.
Conclusion
Compared with standard paclitaxel, Genexol-PM demonstrated non-inferior and even superior clinical efficacy with a manageable safety profile in patients with metastatic breast cancer.

Citations

Citations to this article as recorded by

Revolutionizing cancer treatment: ROS-induced apoptosis via nanoformulated alkaloids
Swathi Putta, Santhosh Kumar Chinnaiyan, Ramadevi Korni, Venkata Radha Gadela
Journal of Drug Delivery Science and Technology.2025; 104: 106556. CrossRef
A drug-eluting balloon catheter coated with chitosan and paclitaxel-loaded poloxamer-stabilized PLA microparticles for the effective treatment of cholangiocarcinoma
Jin Sil Lee, Jaehee Jang, Hyeryeon Oh, Eunhye Lee, Don Haeng Lee, Panmo Son, Daekyung Sung, Won Il Choi
Journal of Industrial and Engineering Chemistry.2025;[Epub] CrossRef
Nanomicellar Prodrug Delivery of Glucose-Paclitaxel: A Strategy to Mitigate Paclitaxel Toxicity
Didi Yan, Xinyue Ma, Yixin Hu, Guogang Zhang, Beibei Hu, Bo Xiang, Xiaokun Cheng, Yongshuai Jing, Xi Chen
International Journal of Nanomedicine.2025; Volume 20: 2087. CrossRef
Administration of Inhibitory Molecules through Nanoparticles in Breast Cancer Therapy
Christian Rafael Quijia, Andreina Quevedo Enríquez, Carlos Daniel Zappia, Roxana Noemí Peroni, Marlus Chorilli
Current Medicinal Chemistry.2024; 31(6): 726. CrossRef
Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
Sławomir Wileński, Agnieszka Koper, Paulina Śledzińska, Marek Bebyn, Krzysztof Koper
Journal of Oncology Pharmacy Practice.2024; 30(2): 367. CrossRef
Effect of zwitterionic sulfobetaine incorporation on blood behaviours, phagocytosis, and in vivo biodistribution of pH-responsive micelles with positive charges
Chengwei Wang, Hao Liu, Hu Lin, Rui Zhong, Hao Li, Jiaxin Liu, Xianglin Luo, Meng Tian
Journal of Materials Chemistry B.2024; 12(6): 1652. CrossRef
Reexamining in vivo fate of paclitaxel-loaded polymeric micelles
Shiqi Lin, Yifei Yu, Ercan Wu, Tianhao Ding, Yuxiu Chu, Feng Pan, Yang Yang, Changyou Zhan
Nano Today.2024; 56: 102255. CrossRef
Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials
Ana Serras, Célia Faustino, Lídia Pinheiro
Pharmaceutics.2024; 16(8): 1047. CrossRef
Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
Giuseppe Longobardi, Thomas Lee Moore, Claudia Conte, Francesca Ungaro, Ronit Satchi‐Fainaro, Fabiana Quaglia
WIREs Nanomedicine and Nanobiotechnology.2024;[Epub] CrossRef
Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer
Jia-xin Qiao, Dong-yan Guo, Huan Tian, Zhan-peng Wang, Qiang-qiang Fan, Yuan Tian, Jing Sun, Xiao-fei Zhang, Jun-bo Zou, Jiang-xue Cheng, Fei Luan, Bing-tao Zhai
Materials Today Bio.2024; 29: 101358. CrossRef
Nanotechnology in cancer therapeutics, diagnosis, and management
Disha Hazarika, Sumit Sarma, Priyanka Shankarishan
BioTechnologia.2024; 105(3): 287. CrossRef
Microwave‐Assisted Synthesis of Porous Biomolecule‐Incorporated Metal‐Organic Frameworks as Efficient Nanocarriers for Anti‐Cancer Drugs
Trang Thi Thu Nguyen, Bao Quang Gia Le, Vy Tran Hanh Nguyen, Jae‐Hyoung Lee, Ngoc Xuan Dat Mai, Linh Ho Thuy Nguyen, Tan Le Hoang Doan
ChemistrySelect.2023;[Epub] CrossRef
Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemo‐ and radioresistances
Prithwish Kola, Prasanth Kumar Bhusetty Nagesh, Pritam Kumar Roy, K. Deepak, Rui Luis Reis, Subhas C. Kundu, Mahitosh Mandal
WIREs Nanomedicine and Nanobiotechnology.2023;[Epub] CrossRef
Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives
Mangala Hegde, Nikunj Naliyadhara, Jyothsna Unnikrishnan, Mohammed S. Alqahtani, Mohamed Abbas, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
Cancer Letters.2023; 556: 216066. CrossRef
Influence of lung cancer model characteristics on tumor targeting behavior of nanodrugs
Weixia Xu, Shengmin Yang, Linwei Lu, Qianzhu Xu, Sunyi Wu, Jianfen Zhou, Jiashen Lu, Xingyan Fan, Nana Meng, Yuan Ding, Xudong Zheng, Weiyue Lu
Journal of Controlled Release.2023; 354: 538. CrossRef
Metastatic Breast Cancer: Review of Emerging Nanotherapeutics
Ranga Dissanayake, Rheal Towner, Marya Ahmed
Cancers.2023; 15(11): 2906. CrossRef
Efficacy and Safety of Nanopaclitaxel Formulation for Cancer Treatment: Evidence From Randomized Clinical Trials
Xiangmin Deng, Xiaoqin Huang, Xiaoyan Dong, Genxiang Mao, Wenmin Xing
Nanomedicine.2023; 18(10): 833. CrossRef
Combination Therapy as a Promising Way to Fight Oral Cancer
João P. N. Silva, Bárbara Pinto, Luís Monteiro, Patrícia M. A. Silva, Hassan Bousbaa
Pharmaceutics.2023; 15(6): 1653. CrossRef
Nano delivery system for paclitaxel: Recent advances in cancer theranostics
Na Ying, Sisi Liu, Mengmeng Zhang, Jing Cheng, Linghuan Luo, Jiayi Jiang, Gaofan Shi, Shu Wu, Jun Ji, Haoyuan Su, Hongzhi Pan, Dongdong Zeng
Colloids and Surfaces B: Biointerfaces.2023; 228: 113419. CrossRef
Current Perspectives on Paclitaxel: Focus on Its Production, Delivery and Combination Therapy
Yibin Liu, Fenglan Zhao, Qibao Wang, Qingjie Zhao, Guige Hou, Qingguo Meng
Mini-Reviews in Medicinal Chemistry.2023; 23(18): 1780. CrossRef
Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review
Sheng Sun, Ye-hui Wang, Xiang Gao, He-yong Wang, Lu Zhang, Na Wang, Chun-mei Li, Shao-quan Xiong
Frontiers in Bioengineering and Biotechnology.2023;[Epub] CrossRef
Paclitaxel prodrug-encapsulated polypeptide micelles with redox/pH dual responsiveness for cancer chemotherapy
Jinyu Liu, Yanhao Zhang, Chao Liu, Yuhao Jiang, Zihao Wang, Xinsong Li
International Journal of Pharmaceutics.2023; 645: 123398. CrossRef
Biodegradable polyester-based nano drug delivery system in cancer chemotherapy: a review of recent progress (2021–2023)
Zongheng Wang, Miaomiao Xiao, Fangliang Guo, Yue Yan, Hong Tian, Qianshi Zhang, Shuangyi Ren, Liqun Yang
Frontiers in Bioengineering and Biotechnology.2023;[Epub] CrossRef
Comparison of triblock copolymeric micelles based on α- and ε-poly(L-lysine): a Cornelian choice
Franck Marquet, Viorica Patrulea, Gerrit Borchard
Polymer Journal.2022; 54(2): 199. CrossRef
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Yike Jiang, Ziyi Jiang, Mingzhe Wang, Lan Ma
Advanced Drug Delivery Reviews.2022; 180: 114034. CrossRef
Poly(ϵ-Caprolactone)-Methoxypolyethylene Glycol (PCL-MPEG)-Based Micelles for Drug-Delivery: The Effect of PCL Chain Length on Blood Components, Phagocytosis, and Biodistribution
Zemin Hou, Wencheng Zhou, Xi Guo, Rui Zhong, Ao Wang, Jiehua Li, Ying Cen, Chao You, Hong Tan, Meng Tian
International Journal of Nanomedicine.2022; Volume 17: 1613. CrossRef
Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy
Prashant Pandey, Dilip Kumar Arya, Mohan Kumar Ramar, Kumarappan Chidambaram, P.S. Rajinikanth
Drug Discovery Today.2022; 27(9): 2526. CrossRef
Biophysical Characterization of Interactions between Serum Albumin and Block Copolymer Micelles
Catherine F. Dial, Richard A. Gemeinhart
ACS Biomaterials Science & Engineering.2022; 8(7): 2899. CrossRef
Micelles in Cancer Therapy: An Update on Preclinical and Clinical Status
Rabia Aqeel, Nidhi Srivastava, Poonam Kushwaha
Recent Patents on Nanotechnology.2022; 16(4): 283. CrossRef
Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
Juanjuan Yang, Xiaojin Wang, Bingshun Wang, Kinam Park, Karen Wooley, Shiyi Zhang
Advanced Drug Delivery Reviews.2022; 190: 114525. CrossRef
In Vivo Sustained Release of the Retrograde Transport Inhibitor Retro-2.1 Formulated in a Thermosensitive Hydrogel
Robin Vinck, Laetitia Anvi Nguyen, Mathilde Munier, Lucie Caramelle, Diana Karpman, Julien Barbier, Alain Pruvost, Jean-Christophe Cintrat, Daniel Gillet
International Journal of Molecular Sciences.2022; 23(23): 14611. CrossRef
Clinical Translation of Self‐Assembled Cancer Nanomedicines
Peng Mi, Kanjiro Miyata, Kazunori Kataoka, Horacio Cabral
Advanced Therapeutics.2021;[Epub] CrossRef
From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
Guillermo Valdivia, Ángela Alonso-Diez, Dolores Pérez-Alenza, Laura Peña
Frontiers in Veterinary Science.2021;[Epub] CrossRef
Advanced Biotechnologies: Collections of Plant Cell Cultures As a Basis for Development and Production of Medicinal Preparations
E. V. Popova, A. V. Nosov, M. V. Titova, D. V. Kochkin, A. A. Fomenkov, I. E. Kulichenko, A. M. Nosov
Russian Journal of Plant Physiology.2021; 68(3): 385. CrossRef
Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation
Xin Luan, Hebao Yuan, Yudong Song, Hongxiang Hu, Bo Wen, Miao He, Huixia Zhang, Yan Li, Feng Li, Pan Shu, Joseph P. Burnett, Nathan Truchan, Maria Palmisano, Manjunath P. Pai, Simon Zhou, Wei Gao, Duxin Sun
Biomaterials.2021; 275: 120910. CrossRef
Breast cancer: Muscarinic receptors as new targets for tumor therapy
Alejandro Español, Agustina Salem, Yamila Sanchez, María Elena Sales
World Journal of Clinical Oncology.2021; 12(6): 404. CrossRef
Direct Comparison of Analogous Amphiphilic Gradient and Block Polyoxazolines
Lenka Loukotová, Pavel Švec, Ondřej Groborz, Tomáš Heizer, Hynek Beneš, Helena Raabová, Tereza Bělinová, Vít Herynek, Martin Hrubý
Macromolecules.2021; 54(17): 8182. CrossRef
Challenges towards Targeted Drug Delivery in Cancer Nanomedicines
Muhammad Nadeem Hafeez, Christian Celia, Vilma Petrikaite
Processes.2021; 9(9): 1527. CrossRef
Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature
Kah Min Yap, Mahendran Sekar, Shivkanya Fuloria, Yuan Seng Wu, Siew Hua Gan, Nur Najihah Izzati Mat Rani, Vetriselvan Subramaniyan, Chandrakant Kokare, Pei Teng Lum, M Yasmin Begum, Shankar Mani, Dhanalekshmi Unnikrishnan Meenakshi, Kathiresan V Sathasiva
International Journal of Nanomedicine.2021; Volume 16: 7891. CrossRef
Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
Sung-Bae Kim, Jae Hong Seo, Jin-Hee Ahn, Tae-Yong Kim, Seok Yun Kang, Joohyuk Sohn, Yaewon Yang, Kyong Hwa Park, Yong Wha Moon, Seungtaek Lim, Myoung Joo Kang, Koung Eun Yoon, Hyun Ju Cho, Keun Seok Lee
Therapeutic Advances in Medical Oncology.2021;[Epub] CrossRef
Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy
Chengyuan Dong, Quan Zhou, Jiajia Xiang, Fusheng Liu, Zhuxian Zhou, Youqing Shen
Journal of Controlled Release.2020; 321: 529. CrossRef
Clinical applications of nanomedicine in cancer therapy
Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian, Fatemeh Atyabi
Drug Discovery Today.2020; 25(1): 107. CrossRef
Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis

Pi-Ling Chou, Ya-Ping Huang, Meng-Hsuan Cheng, Kun-Ming Rau, Yi-Ping Fang
International Journal of Nanomedicine.2020; Volume 15: 1731. CrossRef
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
Adam S. Komorowski, Helen J. MacKay, Rossanna C. Pezo
Cancer Medicine.2020; 9(14): 5035. CrossRef
Nanotechnology for angiogenesis: opportunities and challenges
Saeid Kargozar, Francesco Baino, Sepideh Hamzehlou, Michael R. Hamblin, Masoud Mozafari
Chemical Society Reviews.2020; 49(14): 5008. CrossRef
Furry nanoparticles: synthesis and characterization of nanoemulsion-mediated core crosslinked nanoparticles and their robust stability in vivo
Rena Tanaka, Koichi Arai, Jun Matsuno, Miyo Soejima, Ji Ha Lee, Rintaro Takahashi, Kazuo Sakurai, Shota Fujii
Polymer Chemistry.2020; 11(27): 4408. CrossRef
Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval
Duhyeong Hwang, Jacob D. Ramsey, Alexander V. Kabanov
Advanced Drug Delivery Reviews.2020; 156: 80. CrossRef
What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
Duxin Sun, Simon Zhou, Wei Gao
ACS Nano.2020; 14(10): 12281. CrossRef
Synthesis of PCL–PEG–PCL Triblock Copolymer via Organocatalytic Ring-Opening Polymerization and Its Application as an Injectable Hydrogel—An Interdisciplinary Learning Trial
Kaiting Wu, Lin Yu, Jiandong Ding
Journal of Chemical Education.2020; 97(11): 4158. CrossRef
Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use

Madhusmita Dhupal, Devasish Chowdhury
International Journal of Nanomedicine.2020; Volume 15: 9125. CrossRef
A Compressive Review about Taxol®: History and Future Challenges
Julia Gallego-Jara, Gema Lozano-Terol, Rosa Alba Sola-Martínez, Manuel Cánovas-Díaz, Teresa de Diego Puente
Molecules.2020; 25(24): 5986. CrossRef
Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer
Ruben AG van Eerden, Ron HJ Mathijssen, Stijn LW Koolen
International Journal of Nanomedicine.2020; Volume 15: 8151. CrossRef
Basic principles of drug delivery systems – the case of paclitaxel
S. Ezrahi, A. Aserin, N. Garti
Advances in Colloid and Interface Science.2019; 263: 95. CrossRef
Biomolecules Turn Self-Assembling Amphiphilic Block Co-polymer Platforms Into Biomimetic Interfaces
Saziye Yorulmaz Avsar, Myrto Kyropoulou, Stefano Di Leone, Cora-Ann Schoenenberger, Wolfgang P. Meier, Cornelia G. Palivan
Frontiers in Chemistry.2019;[Epub] CrossRef
Polyester Nanoparticle Encapsulation Mitigates Paclitaxel-Induced Peripheral Neuropathy
R. Ganugula, M. Deng, M. Arora, H.-L. Pan, M. N. V. Ravi Kumar
ACS Chemical Neuroscience.2019; 10(3): 1801. CrossRef
PEGylation of Ginsenoside Rg3-Entrapped Bovine Serum Albumin Nanoparticles: Preparation, Characterization, and In Vitro Biological Studies
Lijun Zhang, Junfeng Hui, Pei Ma, Yu Mi, Daidi Fan, Chenhui Zhu, Lei Chi, Yanan Dong
Journal of Nanomaterials.2019; 2019: 1. CrossRef
Prevention of paclitaxel-induced neuropathy by formulation approach
Xiaowei Zang, Jong Bong Lee, Kiran Deshpande, Olga B. Garbuzenko, Tamara Minko, Leonid Kagan
Journal of Controlled Release.2019; 303: 109. CrossRef
Current status of nanomedicine in the chemotherapy of breast cancer
A. I. Fraguas-Sánchez, C. Martín-Sabroso, A. Fernández-Carballido, A. I. Torres-Suárez
Cancer Chemotherapy and Pharmacology.2019; 84(4): 689. CrossRef
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo
The Oncologist.2019; 24(6): 751. CrossRef
Advances in thermosensitive polymer-grafted platforms for biomedical applications
Phung Ngan Le, Chan Khon Huynh, Ngoc Quyen Tran
Materials Science and Engineering: C.2018; 92: 1016. CrossRef
Supramolecular polymeric chemotherapy based on cucurbit[7]uril-PEG copolymer
Hao Chen, Yueyue Chen, Han Wu, Jiang-Fei Xu, Zhiwei Sun, Xi Zhang
Biomaterials.2018; 178: 697. CrossRef
pH/NIR-Responsive Polypyrrole-Functionalized Fibrous Localized Drug-Delivery Platform for Synergistic Cancer Therapy
Arjun Prasad Tiwari, Tae In Hwang, Jung-Mi Oh, Bikendra Maharjan, Sungkun Chun, Beom Su Kim, Mahesh Kumar Joshi, Chan Hee Park, Cheol Sang Kim
ACS Applied Materials & Interfaces.2018; 10(24): 20256. CrossRef
The Blood Clearance Kinetics and Pathway of Polymeric Micelles in Cancer Drug Delivery
Xuanrong Sun, Guowei Wang, Hao Zhang, Shiqi Hu, Xin Liu, Jianbin Tang, Youqing Shen
ACS Nano.2018; 12(6): 6179. CrossRef
Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles
Feng Li, Huixia Zhang, Miao He, Jinhui Liao, Nianhang Chen, Yan Li, Simon Zhou, Maria Palmisano, Alex Yu, Manjunath P. Pai, Hebao Yuan, Duxin Sun
Molecular Pharmaceutics.2018; 15(10): 4505. CrossRef
Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery
Longfa Kou, Rui Sun, Yangzom D. Bhutia, Qing Yao, Ruijie Chen
Expert Opinion on Drug Delivery.2018; 15(9): 869. CrossRef
The battle of “nano” paclitaxel
Alexandros Marios Sofias, Michael Dunne, Gert Storm, Christine Allen
Advanced Drug Delivery Reviews.2017;[Epub] CrossRef
Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic
Loujin Houdaihed, James C. Evans, Christine Allen
Molecular Pharmaceutics.2017; 14(8): 2503. CrossRef
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
Philip Grossen, Dominik Witzigmann, Sandro Sieber, Jörg Huwyler
Journal of Controlled Release.2017; 260: 46. CrossRef
Effect of Thermoresponsive Poly(L-lactic acid)–poly(ethylene glycol) Gel Injection on Left Ventricular Remodeling in a Rat Myocardial Infarction Model
Shota Somekawa, Atsushi Mahara, Kazunari Masutani, Yoshiharu Kimura, Hiroshi Urakawa, Tetsuji Yamaoka
Tissue Engineering and Regenerative Medicine.2017; 14(5): 507. CrossRef
A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer
Xin-shuai Wang, De-jiu Kong, Tzu-yin Lin, Xiao-cen Li, Yoshihiro Izumiya, Xue-zhen Ding, Li Zhang, Xiao-chen Hu, Jun-qiang Yang, She-gan Gao, Kit S Lam, Yuan-pei Li
Acta Pharmacologica Sinica.2017; 38(6): 931. CrossRef

17,683 View
639 Download
74 Web of Science
70 Crossref

Case Report

A Rare Case of Phyllodes Tumor Metastasis to the Stomach Presenting as Anemia: Do Il Choi, Ho Seok Chi, Sang Ho Lee, Youngmee Kwon, Seog Yun Park, Sung Hoon Sim, In Hae Park, Keun Seok Lee; Cancer Res Treat. 2017;49(3):846-849. Published online September 1, 2016; DOI: https://doi.org/10.4143/crt.2016.188

Abstract PDF PubReader ePub

Metastasis of a phyllodes tumor to the stomach is an extremely rare condition with important clinical implications. A 44-year-old woman was initially diagnosed with a phyllodes tumor in her right breast in 2008, and subsequently presented to an outpatient clinic with dizziness on December 16, 2013. We found that she had severe anemia (hemoglobin levels, 6.7 g/dL), and we quickly performed esophagogastroduodenoscopy to identify the cause. This procedure revealed large ulcerofungating masses with active bleeding in the stomach. Histopathological examination revealed that the masses were consistent with phyllodes tumor metastases. In patients with a metastatic phyllodes tumor presenting as anemia, gastric metastasis should be considered as one of the differential diagnoses because overlooking the possibility might have dire consequences if cytotoxic chemotherapy were administered.

Citations

Citations to this article as recorded by

Unusual Metastatic Sites in Malignant Phyllodes Tumor Detected on FDG PET/CT
Wai Ip Li, Koon Kiu Ng, Ting Kun Au Yong, Boom Ting Kung
World Journal of Nuclear Medicine.2024; 23(02): 147. CrossRef
NKILA is a novel suppressor of local recurrence in women breast malignant phyllodes tumor patients via inhibition of the NF-κB pathway
Ying Mi, Le Yan, Haiyun Jin, Ming Jin, Di Zhu, Hongyan Huang, Kai Han, Jibo Huang
Heliyon.2024; 10(13): e33259. CrossRef
A rare case of metastatic malignant phyllodes tumor with osteosarcomatous differentiation presenting with intestinal obstruction
Neelam R. Bhandari, Manjusha M. Karegar, Pradeep Vaideeswar
Indian Journal of Pathology and Microbiology.2023; 66(1): 184. CrossRef
Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study
Naiquan Liu, Ye Kang, Ningxin Qu, Chenhui Kong, Ye Han
BMC Cancer.2023;[Epub] CrossRef
Metastasis to the stomach: a systematic review
Arturan Ibrahimli, Altay Aliyev, Aykhan Majidli, Aysegul Kahraman, Aysuna Galandarova, Emil Khalilzade, Heydar Mammadli, Kamran Huseynli, Karam Assaf, Cagatay Kilinc, Nijat Muradov, Omer F. Alisan, Sabir Abdullayev, Yeliz I. Sahin, Elgun Samadov
F1000Research.2023; 12: 1374. CrossRef
Significant Antitumor Activity of Pazopanib in a Patient with PDGFRB-Mutated Metastatic Phyllodes Tumor: a Case Report
Mieko Ochi, Shingo Miyamoto, Keita Nakao, Yoshiaki Furuhata, Yusuke Tabei, Shunsuke Ichi, Yuan Bae, Toshio Kumasaka, Shingo Kato, Hideo Kunitoh
SN Comprehensive Clinical Medicine.2021; 3(3): 901. CrossRef
Malignant phyllodes tumor of the breast: case report, tumor characteristics, treatment approach
Łukasz Strzępek, Patrycja Ciesielska, Katarzyna Karakiewicz-Krawczyk, Aleksandra Czerw
Breast Cancer Management.2021;[Epub] CrossRef
A giant malignant phyllodes tumor of breast post mastectomy with metastasis to stomach manifesting as anemia: a case report and review of literature
Hui-Pu Liu, Wen-Yen Chang, Chin-Wen Hsu, Shan-Tao Chien, Zheng-Yi Huang, Wen-Ching Kung, Ping-Hung Liu
BMC Surgery.2020;[Epub] CrossRef
Distant metastases in phyllodes tumours of the breast: an overview
Valerie Cui Yun Koh, Aye Aye Thike, Puay Hoon Tan
Applied Cancer Research.2017;[Epub] CrossRef
Atypical Distant Metastasis of Breast Malignant Phyllodes Tumors: A Case Report and Literature Review
Tiphaine de Foucher, Hélène Roussel, Mikael Hivelin, Léa Rossi, Caroline Cornou, Anne-Sophie Bats, Myriam Deloménie, Fabrice Lécuru, Charlotte Ngô
Case Reports in Obstetrics and Gynecology.2017; 2017: 1. CrossRef

10,394 View
180 Download
10 Web of Science
10 Crossref

Original Articles

Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study: Se Hyun Kim, Kyung Hae Jung, Tae-Yong Kim, Seock-Ah Im, In Sil Choi, Yee Soo Chae, Sun Kyung Baek, Seok Yun Kang, Sarah Park, In Hae Park, Keun Seok Lee, Yoon Ji Choi, Soohyeon Lee, Joo Hyuk Sohn, Yeon-Hee Park, Young-Hyuck Im, Jin-Hee Ahn, Sung-Bae Kim, Jee Hyun Kim; Cancer Res Treat. 2016;48(4):1373-1381. Published online March 23, 2016; DOI: https://doi.org/10.4143/crt.2015.475

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study is to investigate the prognostic value of lymph node (LN) ratio (LNR) in patients with breast cancer after neoadjuvant chemotherapy.
Materials and Methods
This retrospective analysis is based on the data of 814 patientswith stage II/III breast cancer treated with four cycles of doxorubicin/cyclophosphamide followed by four cycles of docetaxel before surgery. We evaluated the clinical significance of LNR (3 categories: low 0-0.20 vs. intermediate 0.21-0.65 vs. high 0.66-1.00) using a Cox proportional regression model.
Results
A total of 799 patients underwent breast surgery. Pathologic complete response (pCR, ypT0/isN0) was achieved in 129 patients (16.1%) (hormone receptor [HR] +/human epidermal growth factor receptor 2 [HER2] –, 34/373 [9.1%]; HER2+, 45/210 [21.4%]; triple negative breast cancer, 50/216 [23.1%]). The mean numbers of involved LN and retrieved LN were 2.70 (range, 0 to 42) and 13.98 (range, 1 to 64), respectively. The mean LNR was 0.17 (low, 574 [71.8%]; intermediate, 170 [21.3%]; high, 55 [6.9%]). In univariate analysis, LNR showed significant association with a worse relapse-free survival (3-year relapse-free survival rate 84.8% in low vs. 66.2% in intermediate vs. 54.3% in high; p < 0.001, log-rank test). In multivariate analysis, LNR did not show significant association with recurrence after adjusting for other clinical factors (age, histologic grade, subtype, ypT stage, ypN stage, lymphatic or vascular invasion, and pCR). In subgroup analysis, the LNR system had good prognostic value in HR+/HER2– subtype.
Conclusion
LNR is not superior to ypN stage in predicting clinical outcome of breast cancer after neoadjuvant chemotherapy. However, the prognostic value of the LNR system in HR+/HER2– patients is notable and worthy of further investigation.

Citations

Citations to this article as recorded by

Breast Cancer Patients With Positive Apical or Infraclavicular/Ipsilateral Supraclavicular Lymph Nodes Should Be Excluded in the Application of the Lymph Node Ratio System
Zhe Wang, Wei Chong, Huikun Zhang, Xiaoli Liu, Yawen Zhao, Zhifang Guo, Li Fu, Yongjie Ma, Feng Gu
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis
Jinzhao Liu, Yifei Li, Weifang Zhang, Chenhui Yang, Chao Yang, Liang Chen, Mingjian Ding, Liang Zhang, Xiaojun Liu, Guozhong Cui, Yunjiang Liu
Frontiers in Surgery.2022;[Epub] CrossRef
Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer
Yul Ri Chung, Ji Won Woo, Soomin Ahn, Eunyoung Kang, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
Scientific Reports.2021;[Epub] CrossRef
Using a novel T-lymph node ratio model to evaluate the prognosis of nonmetastatic breast cancer patients who received preoperative radiotherapy followed by mastectomy
Yang Wang, Yuanyuan Zhao, Song Liu, Weifang Tang, Hong Gao, Xucai Zheng, Shikai Hong, Shengying Wang
Medicine.2017; 96(42): e8203. CrossRef
The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes
Xiang Li, Ruishan Zhang, Zhuangkai Liu, Shuang Li, Hong Xu
Oncotarget.2017; 8(12): 20252. CrossRef
Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
Ji Hyun Chang, Wan Jeon, Kyubo Kim, Kyung Hwan Shin, Wonshik Han, Dong-Young Noh, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang
Journal of Breast Cancer.2016; 19(4): 394. CrossRef

11,968 View
163 Download
7 Web of Science
6 Crossref

Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment: Eunjin Jwa, Kyung Hwan Shin, Ja Young Kim, Young Hee Park, So-Youn Jung, Eun Sook Lee, In Hae Park, Keun Seok Lee, Jungsil Ro, Yeon-Joo Kim, Tae Hyun Kim; Cancer Res Treat. 2016;48(4):1363-1372. Published online February 18, 2016; DOI: https://doi.org/10.4143/crt.2015.456

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to determine whether breast cancer subtype can affect locoregional recurrence (LRR) and ipsilateral breast tumor recurrence (IBTR) after neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). Materials and Methods We evaluated 335 consecutive patients with clinical stage II-III breast cancer who received NAC plus BCT from 2002 to 2009. Patients were classified according to six molecular subtypes: luminal A (hormone receptor [HR]+/HER2–/Ki-67 < 15%, n=113), luminal B1 (HR+/HER2–/Ki-67 ≥ 15%, n=33), luminal B2 (HR+/HER2+, n=83), HER2 with trastuzumab (HER2[T+]) (HR–/HER2+/use of trastuzumab, n=14), HER2 without trastuzumab (HER2[T–]) (HR–/HER2+, n=31), and triple negative (TN) (HR–/HER2–, n=61).
Results
After a median follow-up period of 7.2 years, 26 IBTRs and 37 LRRs occurred. The 5-year LRR-free survival rates were luminal A, 96.4%; B1, 93.9%; B2, 90.3%; HER2(T+), 92.9%; HER2(T–), 78.3%; and TN, 79.6%. The 5-year IBTR-free survival rates were luminal A, 97.2%; B1, 93.9%; B2, 92.8%; HER2(T+), 92.9%; HER2(T–), 89.1%; and TN, 84.6%. In multivariate analysis, HER2(T–) (IBTR: hazard ratio, 4.2; p=0.04 and LRR: hazard ratio, 7.6; p < 0.01) and TN subtypes (IBTR: hazard ratio, 6.9; p=0.01 and LRR: hazard ratio, 8.1; p < 0.01) were associated with higher IBTR and LRR rates. A pathologic complete response (pCR) was found to show correlation with better LRR and a tendency toward improved IBTR controls in TN patients (IBTR, p=0.07; LRR, p=0.03). Conclusion The TN and HER2(T–) subtypes predict higher rates of IBTR and LRR after NAC and BCT. A pCR is predictive of improved IBTR or LRR in TN subtype.

Citations

Citations to this article as recorded by

Prioritizing cases from a multi-institutional cohort for a dataset of pathologist annotations
Victor Garcia, Emma Gardecki, Stephanie Jou, Xiaoxian Li, Kenneth R. Shroyer, Joel Saltz, Balazs Acs, Katherine Elfer, Jochen Lennerz, Roberto Salgado, Brandon D. Gallas
Journal of Pathology Informatics.2025; 16: 100411. CrossRef
Mitomycin C in the treatment of early triple-negative locally advanced BRCA-associated breast cancer
D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, R. V. Donskih, A. P. Sokolenko, V. O. Azaova, N. N. Amirov, Ya. Ig. Bondarchuk, V. E. Levcheko, D. G. Ulrikh, V. F. Semiglazov
Medical alphabet.2024; (7): 13. CrossRef
Tissue- and Temporal-Dependent Dynamics of Myeloablation in Response to Gemcitabine Chemotherapy
Lydia E. Kitelinger, Eric A. Thim, Sarah Y. Zipkowitz, Richard J. Price, Timothy N. J. Bullock
Cells.2024; 13(16): 1317. CrossRef
Risk of locoregional recurrence after breast cancer surgery by molecular subtype—a systematic review and network meta-analysis
Lily Nolan, Matthew G. Davey, Gavin G. Calpin, Éanna J. Ryan, Michael R. Boland
Irish Journal of Medical Science (1971 -).2024; 193(6): 2965. CrossRef
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical
Kelly K. Hunt, Vera J. Suman, Hannah F. Wingate, A. Marilyn Leitch, Gary Unzeitig, Judy C. Boughey, Funda Meric-Bernstam, Matthew J. Ellis, John Olson
Annals of Surgical Oncology.2023; 30(4): 2111. CrossRef
Margin Width and Local Recurrence in Patients Undergoing Breast Conservation After Neoadjuvant Chemotherapy
Mary Mrdutt, Alexandra Heerdt, Varadan Sevilimedu, Anita Mamtani, Andrea Barrio, Monica Morrow
Annals of Surgical Oncology.2022; 29(1): 484. CrossRef
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
Ariane A. van Loevezijn, Marieke E. M. van der Noordaa, Marcel P. M. Stokkel, Erik D. van Werkhoven, Emma J. Groen, Claudette E. Loo, Paula H. M. Elkhuizen, Gabe S. Sonke, Nicola S. Russell, Frederieke H. van Duijnhoven, Marie-Jeanne T. F. D. Vrancken Pee
Breast Cancer Research and Treatment.2022; 193(1): 37. CrossRef
De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study
Sabine R de Wild, Linda de Munck, Janine M Simons, Janneke Verloop, Thijs van Dalen, Paula H M Elkhuizen, Ruud M A Houben, A Elise van Leeuwen, Sabine C Linn, Ruud M Pijnappel, Philip M P Poortmans, Luc J A Strobbe, Jelle Wesseling, Adri C Voogd, Liesbeth
The Lancet Oncology.2022; 23(9): 1201. CrossRef
Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
Anna Baranova, Mykola Krasnoselskyi, Volodymyr Starikov, Sergii Kartashov, Igor Zhulkevych, Vadym Vlasenko, Kateryna Oleshko, Olga Bilodid, Marina Sadchikova, Yurii Vinnyk
Journal of Medicine and Life.2022; 15(2): 153. CrossRef
Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
Makoto Ishitobi, Naoko Matsuda, Mizuho Tazo, Sayuka Nakayama, Ryu Tokui, Tomoko Ogawa, Atsushi Yoshida, Yasuyuki Kojima, Takashi Kuwayama, Takahiro Nakayama, Hideko Yamauchi, Seigo Nakamura, Koichiro Tsugawa, Naoki Hayashi
Annals of Surgical Oncology.2021; 28(5): 2545. CrossRef
Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study
Janine M. Simons, Julien G. Jacobs, Joost P. Roijers, Maarten A. Beek, Leandra J. M. Boonman-de Winter, Arjen M. Rijken, Paul D. Gobardhan, Jan H. Wijsman, Eric Tetteroo, Joan B. Heijns, C. Y. Yick, Ernest J. T. Luiten
Breast Cancer Research and Treatment.2021; 185(2): 441. CrossRef
Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery
Matthew R. Woeste, Neal Bhutiani, Marilyn Donaldson, Kelly M. McMasters, Nicolás Ajkay
Journal of Surgical Oncology.2021; 123(2): 439. CrossRef
Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis
Eduard-Alexandru Bonci, Ștefan Țîțu, Alexandru Marius Petrușan, Claudiu Hossu, Vlad Alexandru Gâta, Morvarid Talaeian Ghomi, Paul Milan Kubelac, Teodora Irina Bonci, Andra Piciu, Maria Cosnarovici, Liviu Hîțu, Alexandra Timea Kirsch-Mangu, Diana Cristina
Medicina.2021; 57(3): 203. CrossRef
Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment
Hsu-Huan Chou, Wei-Shan Chung, Rong-Yao Ding, Wen-Ling Kuo, Chi-Chang Yu, Hsiu-Pei Tsai, Shih-Che Shen, Chia-Hui Chu, Yung-Feng Lo, Shin-Cheh Chen
BMC Surgery.2021;[Epub] CrossRef
Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients
Giuseppe Canavese, Corrado Tinterri, Franca Carli, Elsa Garrone, Stefano Spinaci, Angelica Della Valle, Erika Barbieri, Emilia Marrazzo, Paolo Bruzzi, Beatrice Dozin
European Journal of Surgical Oncology.2021; 47(8): 1920. CrossRef
Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis
Yujie Lu, Yiwei Tong, Jiahui Huang, Lin Lin, Jiayi Wu, Xiaochun Fei, Xiaosong Chen, Kunwei Shen
Cancer Management and Research.2021; Volume 13: 6279. CrossRef
De-escalation of axillary irradiation for early breast cancer – Has the time come?
Elżbieta Senkus, Maria Joao Cardoso, Orit Kaidar-Person, Aleksandra Łacko, Icro Meattini, Philip Poortmans
Cancer Treatment Reviews.2021; 101: 102297. CrossRef
Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival
K. Wimmer, M. Bolliger, Z. Bago-Horvath, G. Steger, D. Kauer-Dorner, R. Helfgott, C. Gruber, F. Moinfar, M. Mittlböck, F. Fitzal
Annals of Surgical Oncology.2020; 27(5): 1700. CrossRef
Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy
Joseph Lin, Kuo-Juei Lin, Yu-Fen Wang, Ling-Hui Huang, Sam Li-Sheng Chen, Dar-Ren Chen
BMC Cancer.2020;[Epub] CrossRef
Identifying Risk Factors for Regional Recurrence in Early-Stage Breast Cancer with pT1-2 and Negative Sentinel Lymph Node Biopsy

Kai-yun You, Zhuo-fei Bi, Lin Ding, Yu-jia Ma, Yi-min Liu, He-rui Yao
Cancer Management and Research.2020; Volume 12: 9211. CrossRef
Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance
Sebastian M. Jud, Reinhard Hatko, Julius Emons, Bianca Lauterbach, Carolin C. Hack, Caroline Preuß, Werner Adler, Matthias W. Beckmann, Felix Heindl
Journal of Clinical Medicine.2020; 9(12): 4033. CrossRef
A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types
Patrick H. Dinkelborg, Meng Wang, Liliana Gheorghiu, Joseph M. Gurski, Theodore S. Hong, Cyril H. Benes, Dejan Juric, Rachel B. Jimenez, Kerstin Borgmann, Henning Willers
Breast Cancer Research and Treatment.2019; 174(3): 605. CrossRef
The reciprocal influences of prognosis between two types of surgical interventions and early breast cancer patients with diverse luminal subtypes
Lin He, Shengnan Zhao, Min Liu, Zhumin Su, Yuanzhong Ren, Yuhua Song
Medicine.2019; 98(11): e14912. CrossRef
Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer
Jin-Sun Ryu, Sung Hoon Sim, In Hae Park, Eun Gyeong Lee, Eun Sook Lee, Yun-Hee Kim, Youngmee Kwon, Sun-Young Kong, Keun Seok Lee
Cancers.2019; 11(4): 574. CrossRef
Partial-Breast Irradiation: Review of Modern Trials
Bindu Manyam, Chirag Shah, Thomas Julian, Frank Vicini
Current Breast Cancer Reports.2019; 11(4): 277. CrossRef
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019
Marc Thill, Christian Jackisch, Wolfgang Janni, Volkmar Müller, Ute-Susann Albert, Ingo Bauerfeind, Jens Blohmer, Wilfried Budach, Peter Dall, Ingo Diel, Peter A. Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Volker Hanf, Nadia Harbeck, Jens Huob
Breast Care.2019; 14(4): 247. CrossRef
The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation
Chirag Shah, Frank Vicini, Simona F. Shaitelman, Jaroslaw Hepel, Martin Keisch, Douglas Arthur, Atif J. Khan, Robert Kuske, Rakesh Patel, David E. Wazer
Brachytherapy.2018; 17(1): 154. CrossRef
Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy
Janet K. Horton, Reshma Jagsi, Wendy A. Woodward, Alice Ho
International Journal of Radiation Oncology*Biology*Physics.2018; 100(1): 23. CrossRef
Risk factors for locoregional disease recurrence after breast‐conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta‐analysis
Antonios Valachis, Eleftherios P. Mamounas, Elizabeth A. Mittendorf, Naoki Hayashi, Makoto Ishitobi, Clara Natoli, Florian Fitzal, Isabel T. Rubio, Daniel G. Tiezzi, Hee‐Chul Shin, Stewart J. Anderson, Kelly K. Hunt, Naoko Matsuda, Shozo Ohsumi, Athina To
Cancer.2018; 124(14): 2923. CrossRef
Margins in Breast-Conserving Surgery After Neoadjuvant Therapy
Jungeun Choi, Alison Laws, Jiani Hu, William Barry, Mehra Golshan, Tari King
Annals of Surgical Oncology.2018; 25(12): 3541. CrossRef
Critical review of axillary recurrence in early breast cancer
Carlos A. Castaneda, Pamela Rebaza, Miluska Castillo, Henry L. Gomez, Miguel De La Cruz, Gabriela Calderon, Jorge Dunstan, Jose Manuel Cotrina, Julio Abugattas, Tatiana Vidaurre
Critical Reviews in Oncology/Hematology.2018; 129: 146. CrossRef
Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy
Seung Hyuck Jeon, Kyung Hwan Shin, Jin Ho Kim, Kyubo Kim, In Ah Kim, Kyung-Hun Lee, Tae-Yong Kim, Seock-Ah Im
Breast Cancer Research and Treatment.2018; 172(3): 619. CrossRef
Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer
Victor E. Chen, Erin F. Gillespie, Kaveh Zakeri, James D. Murphy, Catheryn M. Yashar, Sharon Lu, John P. Einck
Advances in Radiation Oncology.2017; 2(2): 105. CrossRef
Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study
Pauline Gillon, Nathan Touati, Christel Breton-Callu, Leen Slaets, David Cameron, Hervé Bonnefoi
European Journal of Cancer.2017; 79: 226. CrossRef
Age, molecular subtypes and local therapy decision-making
Anne Kuijer, Tari A. King
The Breast.2017; 34: S70. CrossRef
Identification of glycerol-3-phosphate dehydrogenase 1 as a tumour suppressor in human breast cancer
Cefan Zhou, Jing Yu, Ming Wang, Jing Yang, Hui Xiong, Huang Huang, Dongli Wu, Shimeng Hu, Yefu Wang, Xing-Zhen Chen, Jingfeng Tang
Oncotarget.2017; 8(60): 101309. CrossRef
Prognostic significance of PLIN1 expression in human breast cancer
Cefan Zhou, Ming Wang, Li Zhou, Yi Zhang, Weiyong Liu, Wenying Qin, Rong He, Yang Lu, Yefu Wang, Xing-Zhen Chen, Jingfeng Tang
Oncotarget.2016; 7(34): 54488. CrossRef

15,619 View
358 Download
38 Web of Science
37 Crossref

Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane: Hyeon Kang Koh, Kyung Hwan Shin, Kyubo Kim, Eun Sook Lee, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Eui Kyu Chie, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee, Seock-Ah Im, Sung Whan Ha; Cancer Res Treat. 2016;48(2):483-490. Published online June 5, 2015; DOI: https://doi.org/10.4143/crt.2015.111

Abstract PDF PubReader ePub

Purpose
This study evaluated the effect of surgery-radiotherapy interval (SRI) on outcomes in patients treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) and adjuvant four cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of taxane. Materials and Methods From 1999 to 2007, 397 eligible patients were diagnosed. The effect of SRI on outcomes was analyzed using a Cox proportional hazards model, and a maximal chi-square method was used to identify optimal cut-off value of SRI for each outcome.
Results
The median SRI was 6.7 months (range, 5.6 to 10.3 months). A SRI of 7 months was the significant cut-off value for distant metastasis-free survival (DMFS) and disease-free survival (DFS) using a maximal chi-square method. For overall survival, a significant cut-off value was not found. The patients with SRI > 7 months had worse 6-year DMFS and DFS than those with SRI ≤ 7 months on univariate analysis (DMFS, 81% vs. 91%, p=0.003; DFS, 78% vs. 89%, p=0.002). On multivariate analysis, SRI > 7 months did not affect DMFS and DFS. Conclusion RT delayed for more than 7 months after BCS and adjuvant four cycles of AC followed by four cycles of taxane did not compromise clinical outcomes.

Citations

Citations to this article as recorded by

MiR-210 regulates lung adenocarcinoma by targeting HIF-1α
Guolei Cao, Peiwen Fan, Ronghui Ma, Qinghe Wang, Lili He, Haiwen Niu, Qin Luo
Heliyon.2023; 9(5): e16079. CrossRef
Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial
Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
European Journal of Cancer.2022; 174: 153. CrossRef
Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: A Post-Hoc Analysis of a Randomised Controlled Clinical Trial
Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
SSRN Electronic Journal .2022;[Epub] CrossRef
Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women
Oluwole Adeyemi Babatunde, Jan M. Eberth, Tisha Felder, Robert Moran, Samantha Truman, James R. Hebert, Jiajia Zhang, Swann Arp Adams
Journal of Racial and Ethnic Health Disparities.2021; 8(1): 147. CrossRef
How Does the Interval Between Completion of Adjuvant Chemotherapy and Initiation of Radiotherapy Impact Clinical Outcomes in Operable Breast Cancer Patients?
Lu Cao, Cheng Xu, Gang Cai, Wei-Xiang Qi, Rong Cai, Shu-Bei Wang, Dan Ou, Min Li, Kun-Wei Shen, Jia-Yi Chen
Annals of Surgical Oncology.2021; 28(4): 2155. CrossRef
Saving the Breast Saves the Lives of Breast Cancer Patients
Mohammad Esmaeil Akbari, Maryam Khayamzadeh, Hamid Reza Mirzaei, Afshin Moradi, Atieh Akbari, Farid Moradian, Neda Khalili
International Journal of Surgical Oncology.2020; 2020: 1. CrossRef
Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis
Si-Ye Chen, Yu Tang, Shu-Lian Wang, Yong-Wen Song, Hui Fang, Jian-Yang Wang, Hao Jing, Jiang-Hu Zhang, Guang-Yi Sun, Xu-Ran Zhao, Jing Jin, Yue-Ping Liu, Bo Chen, Shu-Nan Qi, Ning Li, Yuan Tang, Ning-Ning Lu, Hua Ren, Zi-Hao Yu, Ye-Xiong Li
Frontiers in Oncology.2020;[Epub] CrossRef
Evaluation of tissue computed tomography number changes and dosimetric shifts after conventional whole-breast irradiation in patients undergoing breast-conserving surgery
Joo Hwan Lee, Dong Soo Lee, So Hyun Park, Young Kyu Lee, Jeong Soo Kim, Yong Seok Kim
Tumor Biology.2018; 40(8): 101042831879188. CrossRef
The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival
Marissa C van Maaren, Reini W Bretveld, Jan J Jobsen, Renske K Veenstra, Catharina GM Groothuis-Oudshoorn, Hendrik Struikmans, John H Maduro, Luc JA Strobbe, Philip MP Poortmans, Sabine Siesling
British Journal of Cancer.2017; 117(2): 179. CrossRef

11,646 View
126 Download
10 Web of Science
9 Crossref

Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome: Siew Kuan Lim, Moo Hyun Lee, In Hae Park, Ji Young You, Byung-Ho Nam, Byeong Nam Kim, Jungsil Ro, Keun Seok Lee, So-Youn Jung, Young Mee Kwon, Eun Sook Lee; Cancer Res Treat. 2016;48(1):133-141. Published online April 7, 2015; DOI: https://doi.org/10.4143/crt.2014.262

Abstract PDF PubReader ePub

Purpose
The aim of this study was to examine molecular subtype conversions in patients who underwent neoadjuvant chemotherapy (NAC) and analyze their clinical implications.
Materials and Methods
We included consecutive breast cancer patients who received NAC at the National Cancer Center, Korea, between August 2002 and June 2011, and had available data on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor status prior to NAC. Molecular subtypes, hormone receptor (HR) status, and ER and PR Allred scores before and after NAC were compared, and the long-term outcomes were analyzed.
Results
Of 322 patients, 32 (9.9%) achieved a pathologic complete response after NAC. HR+/HER2– tumors tended to convert into triple negative (TN) tumors (10.3%), whereas 34.6% of TN tumors gained HR positivity to become HR+/HER2– tumors. Clinical outcomes of molecular subtype conversion groups were compared against patients who remained as HR+/HER2– throughout. The HR+/HER2– to TN group had significantly poorer recurrencefree survival (RFS) (hazard ratio, 3.54; 95% confidence interval [CI], 1.60 to 7.85) and overall survival (OS) (hazard ratio, 3.73; 95% CI, 1.34 to 10.38). Patients who remained TN throughout had the worst outcomes (for RFS: hazard ratio, 3.70; 95% CI, 1.86 to 7.36; for OS: hazard ratio, 5.85; 95% CI, 2.53 to 13.51), while those who converted from TN to HR+/HER2– showed improved comparable survival outcomes.
Conclusion
Molecular subtypes of breast cancers changed frequently after NAC, resulting in different tumor prognostication. Tumor subtyping should be repeated after NAC in patients with breast cancer.

Citations

Citations to this article as recorded by

Molecular Classification of Breast Cancer Using Weakly Supervised Learning
Wooyoung Jang, Jonghyun Lee, Kyong Hwa Park, Aeree Kim, Sung Hak Lee, Sangjeong Ahn
Cancer Research and Treatment.2025; 57(1): 116. CrossRef
Impact of hormone receptor and HER2 conversions on survival after neoadjuvant chemotherapy in breast cancer patients
Ran Feng, Li-Hui Pan, Ya-Rong Yao, Jin-Nan Gao, Xiao-Jun Zhang
Oncology and Translational Medicine.2025;[Epub] CrossRef
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2 positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis
Shunsuke Nakatani, Takuya Hayashi, Keiko Yamamoto, Hideki Maeda
Cancer Treatment Reviews.2025; : 102923. CrossRef
Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients
Mijia Wang, Zhendong Wei, Jixia Kong, Haidong Zhao
Diagnostic Pathology.2024;[Epub] CrossRef
Texture analysis using non-contrast MRI to predict estrogen receptor status in breast cancer lesions: Is it feasible?
F.A. Shokeir, A.H. Elmokadem, N. Soliman, A. Khater, D. Bayoumi
Clinical Radiology.2024; 79(7): e892. CrossRef
Case report: Heterogeneity in the primary lesions of invasive micropapillary breast carcinoma
Yang Fu, Junwei Cui, Jinming Zhou, Fang Li, Jinsong He, Zijian Yang
Current Problems in Cancer: Case Reports.2024; 16: 100321. CrossRef
Breast Panel Biomarker Changes After Neoadjuvant Chemotherapy in Breast Cancer
Kris Raychelle Godoy, Manuelito Madrid
PJP.2024; 9(1): 17. CrossRef
Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients
Sabine Danzinger, Verena Heiss Spornberger, Hannes Vietzen, Kristina Tendl-Schulz, Georg Pfeiler, Christian F. Singer, Michael Seifert
Cancer Treatment and Research Communications.2024; 43: 100886. CrossRef
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy
Sudheer Vemuru, Jin Huang, Kathryn Colborn, YooJin Yoon, Victoria Huynh, Laura Leonard, Gretchen Ahrendt, Nicole Christian, Anosheh Afghahi, Lauren McLemore, Sharon Sams, Sarah Tevis
Breast Cancer Research and Treatment.2023; 200(2): 247. CrossRef
Inflammasomes in breast cancer: the ignition spark of progression and resistance?
Sawsan Elgohary, Hend M. El Tayebi
Expert Reviews in Molecular Medicine.2023;[Epub] CrossRef
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
Jan Paredes Mogica, Haiming Tang, Yuanxin Liang, Minghao Zhong, Pei Hui, Malini Harigopal, Uma Krishnamurti, Neal A. Fischbach, Haiying Zhan
The Breast.2023; 72: 103586. CrossRef
Research Progress and Future Prospect of HER-2 Low Expression Breast Cancer
·米尔扎合买提买吐鲁佰
Advances in Clinical Medicine.2023; 13(10): 16593. CrossRef
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
Elena Guerini-Rocco, Gerardo Botti, Maria Pia Foschini, Caterina Marchiò, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Elena Roz, Alfredo Santinelli, Isabella Sassi, Viviana Galimberti, Luca Gianni, Giuseppe Viale
Tumori Journal.2022; 108(3): 196. CrossRef
HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review
Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen
World Journal of Clinical Cases.2022; 10(1): 260. CrossRef
Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy
Srivarshini Cherukupalli Mohan, Sarah Walcott-Sapp, Minna K. Lee, Marissa K. Srour, Sungjin Kim, Farin F. Amersi, Armando E. Giuliano, Alice P. Chung
Annals of Surgical Oncology.2021; 28(11): 5907. CrossRef
Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience
Saverio Coiro, Elisa Gasparini, Giuseppe Falco, Giacomo Santandrea, Moira Foroni, Giulia Besutti, Valentina Iotti, Roberto Di Cicilia, Monica Foroni, Simone Mele, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi
Diagnostics.2021; 11(12): 2249. CrossRef
Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy—a survey of pathologists in academic institutions across the United States
Sonali Lanjewar, Priyanka Patil, Susan Fineberg
Modern Pathology.2020; 33(1): 91. CrossRef
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
Journal of Pathology and Translational Medicine.2020; 54(1): 34. CrossRef
Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP‐1 and HER2 expression and converted MCF7 breast cancer subtype
Noura Al‐Zeheimi, Sirin A. Adham
British Journal of Pharmacology.2020; 177(9): 2024. CrossRef
Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
Gi Won Shin, Young Mi Park, Tae Hyun Kim, Anbok Lee, Ha Young Park, Hye Kyoung Yoon, Young Jin Heo, Jin Wook Baek, Yoo Jin Lee
Journal of the Korean Society of Radiology.2020; 81(2): 428. CrossRef
A Six-Epithelial–Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer

Li Yuan Wei, Xiao Jun Zhang, Li Wang, Li Na Hu, Xu Dong Zhang, Li Li, Jin Nan Gao
OncoTargets and Therapy.2020; Volume 13: 6497. CrossRef
Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes
Haoyu Wang, Jiejie Yao, Ying Zhu, Weiwei Zhan, Xiaosong Chen, Kunwei Shen
Cancer Medicine.2020; 9(17): 6173. CrossRef
Effect of neoadjuvant therapy on breast cancer biomarker profile
Laura Rey-Vargas, Juan Carlos Mejía-Henao, María Carolina Sanabria-Salas, Silvia J. Serrano-Gomez
BMC Cancer.2020;[Epub] CrossRef
Surrogate Molecular Classification of Invasive Breast Carcinoma: A Comparison Between Core Needle Biopsy and Surgical Excision, With and Without Neoadjuvant Therapy
Andrea Ambrosini-Spaltro, Elena Zunarelli, Stefania Bettelli, Massimo Lupi, Giuditta Bernardelli, Marina Milani, Guido Ficarra
Applied Immunohistochemistry & Molecular Morphology.2020; 28(7): 551. CrossRef
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
Emma Zattarin, Rita Leporati, Francesca Ligorio, Riccardo Lobefaro, Andrea Vingiani, Giancarlo Pruneri, Claudio Vernieri
Cells.2020; 9(12): 2644. CrossRef
Prediction of breast cancer molecular subtypes using radiomics signatures of synthetic mammography from digital breast tomosynthesis
Jinwoo Son, Si Eun Lee, Eun-Kyung Kim, Sungwon Kim
Scientific Reports.2020;[Epub] CrossRef
Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis
Chao Li, Hongwei Fan, Qian Xiang, Ling Xu, Zhuo Zhang, Qianxin Liu, Tongtong Zhang, Jinjie Ling, Ying Zhou, Xia Zhao, Yimin Cui
Breast Cancer Research and Treatment.2019; 178(3): 497. CrossRef
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
Xinyan Li, Mozhi Wang, Mengshen Wang, Xueting Yu, Jingyi Guo, Tie Sun, Litong Yao, Qiang Zhang, Yingying Xu
Journal of Breast Cancer.2019; 22(4): 497. CrossRef
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Jason J. Zoeller, Aleksandr Vagodny, Krishan Taneja, Benjamin Y. Tan, Neil O'Brien, Dennis J. Slamon, Deepak Sampath, Joel D. Leverson, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge
Molecular Cancer Therapeutics.2019; 18(6): 1115. CrossRef
Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
Soomin Ahn, Hyun Jeong Kim, Milim Kim, Yul Ri Chung, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park
Cancer Research and Treatment.2018; 50(4): 1418. CrossRef
Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How?
Lucy M. De La Cruz, Michael O. Harhay, Paul Zhang, Stacy Ugras
Annals of Surgical Oncology.2018; 25(12): 3535. CrossRef
Modern therapies and iatrogenic changes in breast pathology
Elena Provenzano, Sarah E Pinder
Histopathology.2017; 70(1): 40. CrossRef
Biomarkers of residual disease after neoadjuvant therapy for breast cancer
Frederique Penault-Llorca, Nina Radosevic-Robin
Nature Reviews Clinical Oncology.2016; 13(8): 487. CrossRef
CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype
Tuan Zea Tan, He Yang, Jieru Ye, Jeffrey Low, Mahesh Choolani, David Shao Peng Tan, Jean-Paul Thiery, Ruby Yun-Ju Huang
Oncotarget.2015; 6(41): 43843. CrossRef

15,679 View
200 Download
35 Web of Science
34 Crossref

Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy: Myungsoo Kim, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Tae Hyun Kim, Kwan Ho Cho, Kyung Hwan Shin; Cancer Res Treat. 2015;47(3):416-423. Published online November 17, 2014; DOI: https://doi.org/10.4143/crt.2014.079

Abstract PDF PubReader ePub

Purpose
The risk for lymphedema (LE) after neoadjuvant chemotherapy (NCT) in breast cancer patients has not been fully understood thus far. This study is conducted to investigate the incidence and time course of LE after NCT. Materials and Methods A total of 313 patients with clinically node-positive breast cancer who underwent NCT followed by surgery with axillary lymph node (ALN) dissection from 2004 to 2009 were retrospectively analyzed. All patients received breast and supraclavicular radiation therapy (SCRT). The determination of LE was based on both objective and subjective methods, as part of a prospective database. Results At a median follow-up of 5.6 years, 132 patients had developed LE: 88 (28%) were grade 1; 42 (13%) were grade 2; and two (1%) were grade 3. The overall 5-year cumulative incidence of LE was 42%. LE first occurred within 6 months after surgery in 62%; 1 year in 77%; 2 years in 91%; and 3 years in 96%. In a multivariate analysis, age (hazard ratio [HR], 1.66; p < 0.01) and the number of dissected ALNs (HR, 1.68; p < 0.01) were independent risk factors for LE. Patients with both of these risk factors showed a significantly higher 5-year cumulative incidence of LE compared with patients with no or one risk factor (61% and 37%, respectively; p < 0.001). The addition of adjuvant chemotherapy did not significantly correlate with LE. Conclusion LE after NCT, surgery, and SCRT developed early after treatment, and with a high incidence rate. More frequent surveillance of arm swelling may be necessary in patients after NCT, especially during the first few years of follow-up.

Citations

Citations to this article as recorded by

Association between chemotherapy and the risk of developing breast cancer-related lymphedema: a nationwide retrospective cohort study
Sung Hoon Jeong, Seong Min Chun, Hyunji Lee, Miji Kim, Mira Choi, Ja-Ho Leigh
Supportive Care in Cancer.2025;[Epub] CrossRef
Protective Factors Associated with Normal Lymphatic Function After Axillary Lymph Node Dissection for Breast Cancer Treatment
Janet C. Coleman-Belin, Jonathan Rubin, Lillian A. Boe, Richard Diwan, Jasmine J. L. Monge, Dinh-Do Dinh, Emily Bloomfield, Babak Mehrara, Michelle Coriddi
Annals of Surgical Oncology.2025;[Epub] CrossRef
Multimodal treatments and the risk of breast cancer-related lymphedema: insights from a nationally representative cohort in South Korea
Sung Hoon Jeong, Seong Min Chun, Miji Kim, Ye Seol Lee, Jisun Kim, Ja-Ho Leigh, Yoon-Hee Choi
BMC Cancer.2025;[Epub] CrossRef
Impact of neoadjuvant chemotherapy on breast cancer-related lymphedema after axillary lymph node dissection: a retrospective cohort study
Miaomiao Jia, Lihui Pan, Haibo Yang, Jinnan Gao, Fan Guo
Breast Cancer Research and Treatment.2024; 204(2): 223. CrossRef
Incidence and risk factors of breast cancer-related lymphedema in Korea: a nationwide retrospective cohort study
Ha Rim Ahn, Hyeong Eun Jeong, Choyun Jeong, Sang Yull Kang, Sung Hoo Jung, Hyun Jo Youn, Jong Seung Kim
International Journal of Surgery.2024; 110(6): 3518. CrossRef
Incidence of lymphedema related to various cancers
Marie-Eve Letellier, Marize Ibrahim, Anna Towers, Geneviève Chaput
Medical Oncology.2024;[Epub] CrossRef
Age as a risk factor for breast cancer-related lymphedema: a systematic review
Gunel Guliyeva, Maria T. Huayllani, Daniel Boczar, Francisco R. Avila, Xiaona Lu, Antonio Jorge Forte
Journal of Cancer Survivorship.2023; 17(1): 246. CrossRef
Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies
Aomei Shen, Qian Lu, Xin Fu, Xiaoxia Wei, Liyuan Zhang, Jingru Bian, Wanmin Qiang, Dong Pang
Supportive Care in Cancer.2023;[Epub] CrossRef
Beyond cardiomyocytes: Cellular diversity in the heart's response to exercise
Lena E. Trager, Margaret Lyons, Alexandra Kuznetsov, Cedric Sheffield, Kangsan Roh, Rebecca Freeman, James Rhee, J. Sawalla Guseh, Haobo Li, Anthony Rosenzweig
Journal of Sport and Health Science.2023; 12(4): 423. CrossRef
Managing the Morbidity
Giacomo Montagna, Andrea V. Barrio
Surgical Oncology Clinics of North America.2023; 32(4): 705. CrossRef
Risk of Lymphedema and Death after Lymph Node Dissection with Neoadjuvant and Adjuvant Treatments in Patients with Breast Cancer: An Eight-Year Nationwide Cohort Study
Ye-Seul Lee, Yu-Cheol Lim, Jiyoon Yeo, Song-Yi Kim, Yoon Jae Lee, In-Hyuk Ha
Healthcare.2023; 11(13): 1833. CrossRef
Discussion: Variable Anatomy of the Lateral Upper Arm Lymphatic Channel: An Anatomical Risk Factor for Breast Cancer–Related Lymphedema
Mengfan Wu, Shailesh Agarwal
Plastic & Reconstructive Surgery.2023; 152(2): 430. CrossRef
Breast cancer treatment‐related arm lymphoedema and morbidity: A 6‐year experience in an Australian tertiary breast centre
Yang Yang Huang, Pei Yinn Toh, Catherine Hunt, Joshua Tzi Wei Lin, Roshi Kamyab, Ananda Kallyani Ponniah
Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 109. CrossRef
Cancer Rehabilitation Fact Sheet in Korea
Jin A Yoon, Bo Young Hong
Annals of Rehabilitation Medicine.2022; 46(4): 155. CrossRef
Burden of lymphedema in long‐term breast cancer survivors by race and age
Yumeng Ren, Michael A. Kebede, Adeyemi A. Ogunleye, Marc A. Emerson, Kelly R. Evenson, Lisa A. Carey, Sandra C. Hayes, Melissa A. Troester
Cancer.2022; 128(23): 4119. CrossRef
Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies
Ika Nurlaila, Kangsan Roh, Chang-Hwan Yeom, Hee Kang, Sukchan Lee
Frontiers in Pharmacology.2022;[Epub] CrossRef
Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis
Jae Sik Kim, Jin Ho Kim, Ji Hyun Chang, Do Wook Kim, Kyung Hwan Shin
Frontiers in Oncology.2022;[Epub] CrossRef
Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema
Ayako Nakagawa, Hiroshi Fujimoto, Takeshi Nagashima, Takafumi Sangai, Mamoru Takada, Takahito Masuda, Ryotaro Teranaka, Satoshi Ota, Jun Matsushima, Shinsuke Akita, Masayuki Ohtsuka
Breast Cancer.2020; 27(1): 77. CrossRef
A scoring system for predicting the risk of breast cancer-related lymphedema
Fenglian Li, Qian Lu, Sanli Jin, Quanping Zhao, Xueying Qin, Shuai Jin, Lichuan Zhang
International Journal of Nursing Sciences.2020; 7(1): 21. CrossRef
Body Mass Index as a Major Risk Factor for Severe Breast Cancer-Related Lymphedema
Hélène Leray, Julie Malloizel-Delaunay, Amélie Lusque, Elodie Chantalat, Léonard Bouglon, Charlotte Chollet, Benoit Chaput, Barbara Garmy-Susini, Alexandra Yannoutsos, Charlotte Vaysse
Lymphatic Research and Biology.2020; 18(6): 510. CrossRef
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection
Jane M. Armer, Karla V. Ballman, Linda McCall, Pamela L. Ostby, Eris Zagar, Henry M. Kuerer, Kelly K. Hunt, Judy C. Boughey
JAMA Surgery.2019; 154(9): 800. CrossRef
Breast deformation during the course of radiotherapy: The need for an additional outer margin
J. Seppälä, K. Vuolukka, T. Virén, J. Heikkilä, J.T.J. Honkanen, A. Pandey, A. Al-Gburi, M. Shah, S. Sefa, T. Koivumäki
Physica Medica.2019; 65: 1. CrossRef
Current and future perspectives on the evaluation, prevention and conservative management of breast cancer related lymphoedema: A best practice guideline
Nick Gebruers, Hanne Verbelen, Tessa De Vrieze, Lore Vos, Nele Devoogdt, Lore Fias, Wiebren Tjalma
European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 216: 245. CrossRef
Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up
Ana Carolina Padula Ribeiro Pereira, Rosalina Jorge Koifman, Anke Bergmann
The Breast.2017; 36: 67. CrossRef
Risk factors for lymphoedema in women with breast cancer: A large prospective cohort
S.L. Kilbreath, K.M. Refshauge, J.M. Beith, L.C. Ward, O.A. Ung, E.S. Dylke, J.R. French, J. Yee, L. Koelmeyer, K. Gaitatzis
The Breast.2016; 28: 29. CrossRef
Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer
Myungsoo Kim, Kyung Hwan Shin, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Seung Hyun Chung, Yeon-Joo Kim, Tae Hyun Kim, Kwan Ho Cho
Cancer Research and Treatment.2016; 48(4): 1330. CrossRef
Local Treatment of Breast Cancer
Joanne Lester
Seminars in Oncology Nursing.2015;[Epub] CrossRef
Discrepant Trajectories of Impairment, Activity, and Participation Related to Upper-Limb Function in Patients With Breast Cancer
Eun Joo Yang, Eunyoung Kang, Sung-Won Kim, Jae-Young Lim
Archives of Physical Medicine and Rehabilitation.2015; 96(12): 2161. CrossRef

15,019 View
121 Download
30 Web of Science
28 Crossref

Case Report

A Case of Locally Advanced Breast Cancer Complicated by Pulmonary Tumor Thrombotic Microangiopathy: Hak Jin Kim, Mi Hyang Kwak, Sun-Young Kong, Moon-Woo Seong, Han-Sung Kang, Keun Seok Lee, Jungsil Ro; Cancer Res Treat. 2012;44(4):267-270. Published online December 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.4.267

Abstract PDF PubReader ePub

Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, malignancy-related complication that causes marked pulmonary hypertension, right heart failure, and death. We report on a patient with locally advanced breast cancer whose course was complicated by fatal PTTM based on clinical and laboratory findings.

Citations

Citations to this article as recorded by

Pulmonary tumor thrombotic microangiopathy: a systematic review
Rohit H. Godbole, Rajan Saggar, Nader Kamangar
Pulmonary Circulation.2019; 9(2): 1. CrossRef
Microangiopathie thrombotique tumorale pulmonaire
M. Merad, A. Alibay, S. Ammari, S. Antoun, A. Bouguerba, S. Ayed, F. Vincent
Revue des Maladies Respiratoires.2017; 34(10): 1045. CrossRef
Ante-mortem diagnosis of pulmonary tumour thrombotic microangiopathy in a patient with unrecognised extramammary Paget's disease
Aya Banno, Keijiro Chiba, Hiroko Kasai, Keiichi Nagami
BMJ Case Reports.2016; : bcr2016216666. CrossRef
Pulmonary Tumor Thrombotic Microangiopathy Associated with Advanced Gastric Cancer Successfully Treated with Chemotherapy
Seung-Hyun Yoo, Kwonoh Park, Ji Yeon Hong, Ji Yeon Kim, Jang Won Park, Yong Won Park, Kyung-Hun Lee, Kyung-So Jeon
The Ewha Medical Journal.2014; 37(2): 146. CrossRef
A Case of Pulmonary Tumor Thrombotic Microangiopathy Diagnosed by Transbronchial Lung Biopsy and Treated with Chemotherapy and Long-Term Oxygen and Anticoagulation Therapies
Atsushi Kitamura, Naoki Nishimura, Torahiko Jinta, Rika Suda, Yasuhiko Yamano, Genta Ishikawa, Yutaka Tomishima, Tsuyoshi Hamaoka, Koyu Suzuki, Naohiko Chohnabayashi
Case Reports in Pulmonology.2013; 2013: 1. CrossRef

11,426 View
64 Download
5 Crossref

Original Articles

Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast Cancer: Sun-Young Kong, Do Hoon Lee, Eun Sook Lee, Susan Park, Keun Seok Lee, Jungsil Ro; Cancer Res Treat. 2006;38(1):35-39. Published online February 28, 2006; DOI: https://doi.org/10.4143/crt.2006.38.1.35

Abstract PDF PubReader ePub

Purpose

The aim of study was to evaluate the usefulness of serum HER2 as a therapeutic response indicator in patients with HER2 positive metastatic breast cancer (MBC).

Materials and Methods

The levels of serum HER2 and CA15.3 were assayed in 148 serial serum samples from 50 HER2 positive MBC patients at both the baseline and follow-ups. The changes in the levels of serum HER2 and CA15.3 in relation to the tumor responses to the various chemotherapy regimens were monitored.

Results

The levels of serum HER2 and CA15.3 were elevated in 82% and 62% of tissue HER2 positive patients, respectively, prior to therapies, with the changes in both tumor markers showing statistical significance in relation to the tumor responses (p<0.01) in patients with elevated baseline serum markers.

Conclusion

The level of serum HER2 could be a valuable response indicator, not only for trastuzumab containing therapy, but also for other common MBC chemotherapeutic agents. Also, as it is more frequently elevated, the serum level of HER2 may also be a more useful tumor marker than CA15.3 in HER2 positive MBC.

Citations

Citations to this article as recorded by

AlGaN/GaN HEMT Based Biosensor for Detection of the HER2 Antigen Spiked in Human Serum
Shivanshu Mishra, Pharyanshu Kachhawa, Prasenjit Mondal, Surajit Ghosh, Chaturvedula Tripura, Nidhi Chaturvedi
IEEE Transactions on Electron Devices.2022; 69(8): 4527. CrossRef
Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer
Ji-Won Kim, Debora K. Kim, Ahrum Min, Kyung-Hun Lee, Hyun-Jin Nam, Jee Hyun Kim, Jin-Soo Kim, Tae-Yong Kim, Seock-Ah Im, In Ae Park
Journal of Cancer Research and Clinical Oncology.2016; 142(1): 157. CrossRef
The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients
Moo Hyun Lee, So-Youn Jung, Sun Hee Kang, Eun Jin Song, In Hae Park, Sun-Young Kong, Young Mee Kwon, Keun Seok Lee, Han-Sung Kang, Eun Sook Lee, Aamir Ahmad
PLOS ONE.2016; 11(10): e0163370. CrossRef
HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis
Qian-Qian Xu, Bo Pan, Chang-Jun Wang, Yi-Dong Zhou, Feng Mao, Yan Lin, Jing-Hong Guan, Song-Jie Shen, Xiao-Hui Zhang, Ya-Li Xu, Ying Zhong, Xue-Jing Wang, Yan-Na Zhang, Qiang Sun
Oncotarget.2016; 7(39): 63571. CrossRef
Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
Maria Soares, Rita Ribeiro, Shabir Najmudin, Andreia Gameiro, Rita Rodrigues, Fátima Cardoso, Fernando Ferreira
Oncotarget.2016; 7(14): 17314. CrossRef
A comparative study of disease genes and drug targets in the human protein interactome
Jingchun Sun, Kevin Zhu, W Jim Zheng, Hua Xu
BMC Bioinformatics.2015;[Epub] CrossRef
Classification of Cancer Primary Sites Using Machine Learning and Somatic Mutations
Yukun Chen, Jingchun Sun, Liang-Chin Huang, Hua Xu, Zhongming Zhao
BioMed Research International.2015; 2015: 1. CrossRef
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
Ji-Won Kim, Jee Hyun Kim, Seock-Ah Im, Yu Jung Kim, Hye-Suk Han, Jin-Soo Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Yoon Kyung Jeon, Do-Youn Oh, Tae-You Kim, In Ae Park
Cancer Chemotherapy and Pharmacology.2013; 72(1): 109. CrossRef
Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy
Ji-Won Kim, Jee Hyun Kim, Seock-Ah Im, Kyung-Hun Lee, Jin-Soo Kim, Tae-Yong Kim, Sae-Won Han, Yoon Kyung Jeon, Do-Youn Oh, Tae-You Kim, In Ae Park
Cancer Chemotherapy and Pharmacology.2013; 72(5): 1023. CrossRef
ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy
Ji-Won Kim, Jee Hyun Kim, Seock-Ah Im, Yu Jung Kim, Hye-Suk Han, Jin-Soo Kim, Sae-Won Han, Yoon Kyung Jeon, Do-Youn Oh, Wonshik Han, Tae-You Kim, In Ae Park, Dong-Young Noh, Yung-Jue Bang
Oncology.2012; 83(4): 218. CrossRef
In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models
Guodong Shen, Hui Huang, Anli Zhang, Ting Zhao, Siyi Hu, Liansheng Cheng, Jing Liu, Weihua Xiao, Bin Ling, Qiang Wu, Lihua Song, Wei Wei
Cancer Immunology, Immunotherapy.2011; 60(3): 339. CrossRef
Serum HER2 Level Measured by Dot Blot: A Valid and Inexpensive Assay for Monitoring Breast Cancer Progression
Li-Duan Tan, Yuan-Yuan Xu, Yue Yu, Xiao-Qing Li, Ying Chen, Yu-Mei Feng, Irina Lebedeva
PLoS ONE.2011; 6(4): e18764. CrossRef

10,620 View
63 Download
12 Crossref

A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer: Jung Ae Lee, Keun Seok Lee, Jin Seok Ahn, Jae Ho Byun, Hun Ho Song, Dae Young Zang, Young Iee Park, Young Suk Park, Eun Kyung Mo, Dong Kyu Kim, Myung Goo Lee, In Gyu Hyun, Ki Suck Jung, Soo Mee Bang, Gye Young Park, Jeong Woong Park, Eun Kyung Cho, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee; Cancer Res Treat. 2003;35(3):239-244. Published online June 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.3.239

Abstract PDF

PURPOSE
Paclitaxel and cisplatin, active drugs in the treatment of non-small-cell lung cancer (NSCLC), have been found to be synergistic and less myelotoxic in combination when the paclitaxel is given 24 hr prior to the cisplatin. Their antitumor activity and toxicity in patients with advanced NSCLC has been evaluated herein. MATERIALS AND METHODS: Seventy-four chemonaive patients, with advanced NSCLC, were enrolled. Paclitaxel, 175 mg/m2, was administered on day 1, followed 24 hr later by cisplatin, 75 mg/m2, on day 2. RESULTS: The overall response rate, median time to progression and median survival time were 51%, 7.1 months (95% confidence interval (CI), 5.5~8.7 months) and 13.7 months (95% CI, 11.3~16.1 months), respectively. There were significant differences in the overall survival rates in relation to stage and the ECOG performance status(PS). The toxicity was mainly nonhematological. Grade > or =3 neuropathy occurred in 2 (3%) patients, myalgia in 3 (4%), and bone pain in 3 (4%). The hematological toxicity was mild, and no grade 3 or 4 neutropenia was observed.
CONCLUSION
The combination of paclitaxel and cisplatin is an effective and tolerable treatment regimen for advanced NSCLC during first line chemotherapy. The main toxicity was nonhematological, such as peripheral neuropathy, myalgia and bone pain, whereas the hematological toxicity itself was mild.

Citations

Citations to this article as recorded by

The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
Cancer Research and Treatment.2006; 38(2): 66. CrossRef

4,935 View
32 Download
1 Crossref

A Phase II Study of Ifosfamide, Carboplatin, and Epirubicin (ICE) Combination Chemotherapy for Extensive Disease of Small Cell Lung Cancer: Jae Ho Byun, In Sook Woo, Hun Ho Song, Keun Seok Lee, Jin Seok Ahn, Dae Young Jang, Jung Ae Lee, Young Lee Park, Young Suk Park; Cancer Res Treat. 2002;34(6):416-420. Published online December 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.6.416

Abstract PDF: PURPOSE
To evaluate the efficacy and safety of ifosfamide, carboplatin and epirubicin (ICE) combination chemotherapy for extensive disease small cell lung cancer (SCLC) patients, who had received no previous chemotherapy, we performed phase II trial between August 1998 and January 2001.
MATERIALS AND METHODS
The study group comprised of 21 patients. Ifosfamide, 1,500 mg/m2, was given with mesna, 900 mg/m2, intravenously for 12 hours on days 1, 2 and 3, and carboplatin, 4.5 mg/ml/min, for target AUC, and epirubicin, 60 mg/m2, were given intravenously for 90 minutes on day 1. The cycle of treatment was repeated at 4 week intervals.
RESULTS
Twenty-one patients with extensive disease SCLC were treated at Hallym University between August 1998 and January 2001. One patient was unable to be evaluated because of lost to follow-up. Of the 20 patients able to be evaluated, an objective response was observed in 13 (65%). There were no complete responses. The median response duration, time to progression and median overall survival were 15.4, 18.3 and 34 weeks, respectively. Toxicities were acceptable, with dose reduction for myelosuppression necessary in only a minority of the patients. A total of 85 cycles of chemotherapy were given to the patients. The median number of cycles completed was 4. Grade III and IV hematological toxicities included anemia (4.7%), neutropenia (3.5%) and thrombocytopenia (3.5%). Most non-hematological toxicities were grade I or II.
CONCLUSION
These results suggested that ICE combination chemotherapy for extensive disease SCLC is effective, and can be safely administered with acceptable toxicities.

4,298 View
24 Download

A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer: Won Sup Lee, Keun Seok Lee, Ki Hyun Kim, Baek Yeol Ryoo, Won Seog Kim, Won Ki Kang, Yoon Koo Kang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2001;33(3):225-228. Published online June 30, 2001; DOI: https://doi.org/10.4143/crt.2001.33.3.225

Abstract PDF: PURPOSE
To determine the efficacy and toxicity of UFT-E plus oral calcium leucovorin in the treatment of patients with advanced colorectal cancer.
MATERIALS AND METHODS
Forty-three patients with advanced, bidimensionally measurable colorectal adenocarcinoma were enrolled in the trial. No patients had received prior palliative chemotherapy. The patients that had received previous adjuvant chemotherapy were enrolled when more than 6 months had elapsed after the completion of adjuvant therapy. Patients were treated with 300 mg/m2/day of UFT-E (tegafur-based) plus 90 mg/day of leucovorin administered orally in three divided daily doses, every 8 hours for 28 days followed by a 7-day rest period. Response was evaluated after two or three courses of therapy.
RESULTS
Thirty-six of forty-three patients were evaluable for response; seven dropped out due to infection, toxicity and patients' refusal. Ten patients had partial responses and one patient complete response (response rate, 31%; 95% confidence interval, 16~46%). The median response duration for the UFT-E plus leucovorin regimen was 28 weeks. Grade III toxicity was seen in one case, with diarrhea.
CONCLUSION
This oral regimen proved effective and well tolerated. This schema also avoided inconveniences, such as hospitalization and the use of infusion pumps, which are associated with 5-FU infusion regimens. The regimen used showed minimal toxicity, especially in the upper digestive tract, with good patient compliance.

4,091 View
21 Download

A Phase II Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in 5- Fluorouracil-Pretreated Metastatic Colorectal Cancer: Keun Seok Lee, Won Sup Lee, Hark Kyun Kim, Joo Young Jeong, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 2001;33(2):99-105.

Abstract PDF: PURPOSE
To evaluate antitumor response, time to progression, and toxicities of oxaliplatin, 5- fluorouracil (5-FU), and leucovorin (LV) continuous infusion in patients with metastatic colorectal cancer who progressed during or after treatment with a 5-FU-containing regimen.
MATERIALS AND METHODS
Forty-eight patients with metastatic colorectal cancer, who progressed while receiving or after discontinuing palliative chemotherapy with 5- FU-based regimen, were enrolled in this study. Treatment consisted of oxaliplatin (85 mg/m2 on day 1) as a 2-hour infusion followed by bolus 5-FU (400 mg/m2 on day 1), and 5-FU 48-hour infusion 2.4~3 g/m2 concurrently with LV 48-hour infusion 150 mg/m2, without mixing. Cycles were repeated at 2-week intervals. The dose of 5-FU was modified, depending on the hematologic toxicity profile.
RESULTS
The objective response rate was 28% for 43 assessable patients (95% confidence interval, 14% to 42%), including one complete remission (2%). Seventeen additional patients (39%) had stable disease, and fourteen (33%) progressed. The median time to progression was 5.9 months and the median overall survival was 13.2 months from the start of the chemotherapy. From the 297 cycles analyzed, hematologic toxicities per course were: leukopenia; grade I 26.6%, grade II 3.4%, and grade III 0.3%, thrombocytopenia; grade I 10.8%, grade II 3.0%, grade III 1.0%, and grade IV 0.3%. The most frequent nonhematologic adverse reactions were nausea/vomiting and peripheral neuropathy, which were rated as WHO grade II in 13 patients (49%) and 11 patients (22%), respectively.
CONCLUSION
This phase II study of oxaliplatin, 5-FU, and LV continuous infusion showed enhanced antitumor activity in patients with 5-FU-pretreated metastatic colorectal cancer. Overall toxicity was acceptable; neurotoxicity and bone marrow suppression constituted the dose-limiting side effects.

3,175 View
20 Download

Prognostic Factors of Gastrointestinal Leiomyosarcoma in Korea: Se Hoon Lee, Hee Jeoung Cha, Jee Hyun Kim, Im Il Na, Jun Hee Lee, Hark Kyun Kim, Keun Seok Lee, Won Sup Lee, Chong Jai Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 2000;32(6):1022-1030.

Abstract PDF: PURPOSE
The clinicopathologic features and prognostic factors of gastrointestinal leiomyosarcoma have been a source of controversy.
MATERIALS AND METHODS
A retrospective study was made of 91 incident cases of gastrointestinal leiomyosarcoma from 1979 to 1998 to identify clinicopathologic features and prognostic factors.
RESULTS
The median age of study subjects was 56 years and 58.2% was male. Tumors consisted of 2 esophagus, 39 stomach, 38 small bowel, 12 large bowel leiomyosarcoma. Mean size of the tumors was 10.9 cm and 52.9% of them was larger than 10 cm. The tumors were classified as localized stage (42 cases), advanced stage (21 cases), and metastatic stage (28 cases). Again, the tumors were classified as low grade (48 cases) and high grade (18 cases). Median overall survival was 37.4 months and median disease-free survival was 28.2 months. In univariate analysis, the significant factors affecting the overall survival of patients with leiomyosarcoma were stage, size greater than 10 cm, performance status, and histologic grade. In multivariate analysis, stage, performance status, and histologic grade were independent factors affecting the overall survival. In univariate analysis, the significant factors affecting the disease-free survival were stage, performance status, and histologic grade. In multivariate analysis, histologic grade was the only independent factor affecting the disease-free survival.
CONCLUSION
Stage, performance status, and histologic grade were independent factors affecting the overall survival. Histologic grade was independent factor affecting the disease-free survival.

2,841 View
14 Download

Clinical Characteristics and Prognostic Factors of Metastatic Tumor of Unknown Primary: Eun Kyung Cho, Keun Seok Lee, Chul Won Jung, Won Seog Kim, Ki Hyeong Lee, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(3):607-616.

Abstract PDF: PURPOSE
For malignant diseases, predictions about tumor behavior and determination of appropriate therapy are based on the primary tumor sites, but 2-9% of cancer patients are diagnosed without identifiable primary tumor sites. Metastatic tumors of unknown primary origin (MUO) are a heterogeneous group of tumors with variable natural histories. The majority of these patients fall outside of treatable subjects and seldom respond to therapy. To define further the natural history of MUO and identify prognostic factors, we undertook a clinical analysis of 141 consecutive patients with a presumed diagnosis of MUO.
MATERIALS AND METHODS
One hundred forty-one patients were diagnosed with unknown primary tumor from Jan. 1, 1992 through Aug. 31, 1995. The primary end point for the study was survival, which was calculated from the first day of patient registration diagnosed histologically. The survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. To identify important prognostic factors, univariate and multivariate analyses were conducted.
RESULTS
Most of the 141 patients had histologic or cytologic evidence of adenocarcinoma and had more than one site metastatically involved. The predominant sites of tumor involvement were lymph node, peritoneum, bone, liver, lung, and pleura. Univariate and multivariate analyses identified numerous important prognostic factors with a significant influence on survival, including performance status (P 0.0001), specific organ sites involved (lung P 0.0076 or liver P 0.0310), and chemotherapy group (P- 0.0480).
CONCLUSION
This study validated clinical courses and important prognostic factors that had an impact on survival in MUO.

2,729 View
14 Download

COPP/ABV Hybrid Chemotherapy in Pateints with Hodgkin's Disease: Jin Seok Ahn, Keun Seok Lee, Jong Tae Lee, Seok Ah Lim, Dae Seok Heo, Young Joo Bang, Sun Yang Park, Byung Kook Kim, No Kyung Kim; J Korean Cancer Assoc. 1998;30(4):818-826.

Abstract PDF: PURPOSE
MOPP/ABV hybrid regimen incorporates MOPP and ABVD into a single regimen on the tenets of the Goldie-Coldman hypothesis. This study was performed to determine the efficacy of COPP/ABV hybrid regimen, in which cyclophosphamide was substituted for mechlorethamine, in patients with advanced Hodgkin's disease.
MATERIALS AND METHODS
Patients with advanced Hodgkin's disease were treated with cyclophosphamide(600 mg/m2 iv, Dl), vincristine(1.4 mg/m2 iv, D1), procarbazine(100 mg/m2/d po, D1-7), prednisolone(40 mg/m2/d po D1-14), doxorubicin(35 mg/m2 iv, D8), bleomycin(10 mg/m2 iv, D8) and vinblastine(6 mg/m2 iv, D8). The treatment was repeated every 4 weeks.
RESULTS
Between Aug. 1989 and Aug. 1996, 28 patients were enrolled. The median age was 33 years. Twenty one(75%) were previously untreated, newly diagnosed patients and 7(25%) were those who had relapsed after previous radiotherapy(RT). The common histologic types were nodular sclerosis(46%) and mixed cellularity(36%). Twenty three (82%) patients achieved complete remission(CR), three(11%) with the assistance of involved-field RT. Only one patient was primary treatment failure. The median follow-up duration was 56 months. Of the 23 patients achieving CR, three(13%) relapsed. Five-year relapse-free survival was 84.4%. Eight patients died. Five-year overall survival rate was 66.6% and 5-year failure-free survival rate was 66.3%. The survival rate of those who had relapsed after previous RT was significantly lower than that of newly diagnosed patients(P=0.03). The hematologic toxicities were common, but nonhernatologic toxicities were uncommon. Five patients died of treatment-related pneumonia or sepsis. Among them, four were those who had relapsed after previous RT.
CONCLUSION
COPP/ABV hybrid regimen could cure significant proportion of patients with advanced Hodgkin's disease but the treatment-related mortality was high, especially in those who had relapsed after previous RT. Another regimen should be considered for those who received previous RT.

5,295 View
88 Download

Peripheral T - cell Lymphomas Presenting as Fever of Unknown Origin: Dae Seog Heo, Keun Seok Lee, Joor Yung Huh, Yung Jue Bang, Seon Yang Park, Chul Woo Kim, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1998;30(2):329-337.

Abstract PDF: PURPOSE
Peripheral T-cell lymphomas(PTCL) show diverse clinical and histological characteristics and should be understood as mixtures of heterogeneous entities. Although many clinical and biological parameters have been proposed for classifying PTCL into different prognostic groups, few parameters have turned out to be appropriate for classification. To investigate the clinical significance of FUO presentation in PTCL, comparisons of clinical parameters were performed using non-FUO presentation as a control.
MATERIALS AND METHODS
66 cases of Korean PTCL were divided into FUO group and non-FUO group according to the presentation and compared with each other.
RESULTS
Among 66 patients of PTCL, 19 patients presented with FUO. Compared with non-FUO group, FUO group showed no significant age and sex ratio differences. FUO group showed more advanced stage, worse performance status than non-FUO group. Predominant sites of definite diagnosis were skin, gastrointestinal tract and liver in FUO group and nasal cavity and paranasal sinus in non-FUO group. There were no significant differences between histologic classifications of both groups. Survival analysis revealed significant differences between both groups. FUO group showed significantly shorter survival. Prognostic factor analysis(multivariate) was done with stage, LDH level, performance status, and FUO status. FUO status, stage and performance status were significant determinants of survival, but LDH level proved to have no prognostic implication.
CONCLUSION
PTCL with FUO presentation showed such distinct characteristics that the authors propose fever of unknown origin(FUO) as a clinical parameter for classifying PTCL. Further studies are needed to identify biological parameters which characterize PTCL with FUO presentation.

2,856 View
21 Download

Combination Chemotherapy with 5-Fluorouracil and Carboplatin for Advanced Head and Neck Cancer: Eun Kyung Cho, Won Sup Lee, Chul Won Jung, Keun Seok Lee, Won Seog Kim, Ki Hyeong Lee, Dae Seog Heo, Yung Jue Bang, Kwang Hyun Kim, Charn II Park, Noe Kyeong Kim; J Korean Cancer Assoc. 1996;28(1):94-104.

Abstract PDF: Twenty-nine patients with previously untreated, locally advanced head and neck cancer were treated with two or three cycles of combination chemotherapy consisting of 5- fluorouracil infusion and carboplatin, followed by surgery and/or curative radiotherapy. Nine patients with recurrent head and neck cancer were treated with the same combination chemotherapy. The results were as follows; 1) Among 28 evaluable patients, response rate was 71.4%(partial response) after neoadjuvant chemotherapy. Following local modality(surgery and/or radiotherapy), response rate was 79%(complete response 51.4%, and partial response 25%). 2) One year survival rate in neoadjuvant group was 83% and one year progression-free survival rate, 68.8%. The progression-free survival of responders was significantly prolonged in comparison with that of non-responders(p<0.05). 3) In palliative treatment group, one partial response(11%) was observed among nine patients. Median time to progression was 6.8 weeks and median survival was 17.7 weeks; there was no significant difference between responders and non-responders. 4) Nausea and vomiting were frequently observed but easily controlled. Hematologic toxicities-leukopenia and thrombocytopenia were observed but were reversible. In conclusion, combination chemotherapy with carboplatin and 5-FU was effective for locally advanced head and neck cancer in neoadjuvant setting, but it had limited benefits for recurrent diseases. Toxicities were tolerable and neurotoxicity, ototoxicity, and nephrotoxicity were not observed.

3,512 View
25 Download

Neoadjuvant Chemotherapy with High-dose Methotrexate , Adriamycin and Cisplatin for Non - Metastatic Osteosarcoma: Keun Seok Lee, Heung Moon Chang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim, Sang Hoon Lee, Eui Keun Ham, Han Ku Lee; J Korean Cancer Assoc. 1996;28(6):1092-1104.

Abstract PDF: three non-metastatic osteosarcoma patients were treated with high-dose methotrexate, adriamycin, and cisplatin from October 1987 to May 1993. Median age was 18. The ratio of male to female was 16: 7. The patients received methotrexate 8g/§³ IV, day 1 and 8 with leucovorin rescue, adriamycin 25mg/§³ IV day 16~18, and cisplatin 75mg/§³ IV day 16, After two cycles of neoadjuvant chemotherapy, operation was done and then six cycles of adjuvant chemotherapy were given with the same regimen. One patient developed lung metastasis after two cycles of neoadjuvant chemotherapy, and the other patient died from sepsis associated with chemotherapy-induced neutropenia before operation. Therefore, 21 patients underwent operation. Among them, l9 patients underwent limb salvage operation. Of the five patients who relapsed, two patients had lung metastasis and another two patients had local recurrence, and one patient had both lung and brain metastasis. One year, three year, and five year disease-free survival rate were 84%, 68%, and 68%. One year, three year, and five year survival rate were 91%, 64%, and 53%, respectively. The site of the primary lesion was the only significant prognosis factor. Patients with the lesion of distal femur had poor prognosis.Histologic responses were assessed in 17 patients. Observed histologic responses were grade I necrosis in 35%, grade II necrosis in 65%. There was no grade III or IV necrosis. The disease-free survival rates and overall survival rates were not significantly different between grade I necrosis group and grade II necrosis group. Toxicities grade III or IV were as follows: leukopenia 32%, thrombocytopenia 9%, hepatotoxicity 14%, and infection 6% with one chemotherapy-related death. The pharmacokinetics of high-dose methotrexate with leucovorin rescue were studied in l0 patients. The highest concentration was achieved at the end of infusion(6 hour). The decay of the plasma concentration of methotrexate after completion of the infusion followed a two-compartment model with a T(1/2)￥a of 3.4¡¾1.9 hours and T(1/2)￥a of 8.0¡¾2.6 hours. The clearance was 55¡¾13ml/min/§³ and the volume of distribution was 8.2¡¾3.0 L/§³. In conclusion, neoadjuvant chemotherapy with high-dose methotrexate, adriamycin, and cisplatin is effective for treatment of the patients of osteosarcoma with preserving the limb function.

2,933 View
17 Download

First
Prev
Page of 1
Next
Last

Search